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DOXORUBICIN (D) TO TAXOTERE¿ (T) IN
PREVIOUSLY UNTREATED SOFT TISSUE
SARCOMAS (STS)
J.Verweij, I. Judson, M. Lee,W. Ruka, J. Buesa,
R. Coleman, E. di Paola, D. Locci-Tonelli,
M. van Glabbeke,T.Tursz
The EORTC Soft Tissue and Bone Sarcoma Group
(STBSG), 1200 Brussels, Belgium
STBSG previously reported activity of T in 2nd line
chemotherapy. In order to establish the ® rst line activity of
T in STS we performed a randomized study comparing to
D given as a dose of 75 mg/m
2 iv bolus every 3 weeks to T
given at a dose of 100 mg/m
2 as 1-hr infusion every 3
weeks with corticosteroid comedication, in chemotherapy-
nonpretreated patients (pts). At progression, cross-over to
the other treatment arm was allowed. Eighty-six pts (43 on
D, 43 on T) were entered on study. Median age was 52
years (range 20± 76), medianWHO PS 1 (range 0± 2), 60%
were males, 34% of tumors were leiomyosarcomas and
50% of pts had lung metastases. At present 81 pts are fully
evaluable.The median nr. of courses received was 3 for D
(range 1± 7) and 2 forT (range 1± 7).Achieved dose intensity
(DI) over all cycles was 98% from projected DI for D and
99% for T. On a per patient basis the median granulocyte
nadir was 0.6 (range 0.0± 5.3 3 10
9/l) for T and 0.5 (range
0.1± 8.4) for D, the febrile neutropenia rate being 12% and
22% respectively.
D was more emetogenic (75 vs 27%) and induced more
stomatitis (64 vs 47%, mainly grade 1/2), while T induced
more diarrhea (59 vs 37%) and edema (37 vs 22%, mainly
mild to moderate). Objective partial responses were seen in
13 pts (30%, 95%, CI: 17± 46%) on D and none on T.
Stable disease was seen in 50% of pts on D and 44% on T.
Median TTP was 6 months for D and 2 months for T
(p=0.02).
Thirty-two patients crossed-over to the other study arm
after previous failure.There were 2 PRs (13%) in 16 pts on
second line D and no responses in 16 pts on second line T.
While the activity of D was once again con® rmed, T
appears to be inactive in STS.
EPIDEMIOLOGIC ASPECTS OF SOFT
TISSUE SARCOMAS (STS)Ð
CONSEQUENCES FOR FUTURE CLINICAL
STS-TRIALS
P. Nijhuis, M. Schaapveld, R. Otter, H. Hoekstra
Dept. of Surgical Oncology, Groningen University
Hospital, and the CCCN, PO Box 30.001, 9700 RB,
Groningen,The Netherlands
Introduction: Only limited valid data regarding epidemio-
logic and treatment-related aspects of STS are available.
The purpose of this study was to gain insight into these
aspects, based on the population-based cancer registry of
the Comprehensive Cancer Center North-Netherlands
(CCCN).
Methods:The CCCN Cancer Registry is based on data of
all yearly diagnosed cancer pts in the 19 hospitals, covering
an area of 2.1 million people. All registered, 391 primary
STS, with exception of urogenital and gastrointestinal STS,
diagnosed between 1989± 95 were analyzed with respect to
incidence, sex and age distribution, anatomical site,
histology, tumor size, initial metastases, and treatment
performed.
Results: Incidence STS: 3/100.000/yr. Sex ratio:
205?:186/. Age distribution: 0± 19 yrs:7%, 20± 69 yrs:58%,
70+yrs: 35%. Primary site: trunk 31%, lower limb 29%,
upper limb 15%, head/neck 14.5%, retroperit. 9%, nos
1.5%. Histology: MFH 21%, liposarc. 21%, leiomyosarc.
18%, dermato® brosarc. 17%, ® brosarc. 8%, rhabdomy-
osarc. 6%, nos 9%. Histological distribution equal in both
sexes. Other analysis-based data:
Sex-incidence ? 3.4/100.000/yr; / 2.7/100.000/yr NS
Age-incidence 0± 19 yrs: 0.8; 20± 69 yrs: 2.9; 70+: 11.8 P<.001
Primary site ?: arms and head/neck; /: legs P=.04
Histology (i) leiomyosarcomas in retroperitoneum;
liposarcomas in retroperit. and legs
P<.001
Histology (ii) <10 yrs: rhabdoymosarcomas; 70+:
® bro- & leiomyosarcomas
P<.001
Tumor size head/neck:T1; retroperitoneum:T2 P<.001
Incidence lymph node metastases 2.1%, distant metastases
2.3%. Treatment: 318 pts curative intent (81%), 41 pts
palliative (11%), 32 pts no treatment (8%); older pts
received more often palliative or no treatment at all.
Conclusion: Incidence of STS is signi® cantly increasing
with age, whereas, in the meantime, older pts more often
receive no treatment. It is therefore expected that a
substantial proportion of pts with STS cannot be treated in
scienti® c studies, since most protocols exclude pts above
65 years.Slow accrual for such studies is therefore expected.
Most patients are treated with curative intent (81%). Initial
lymph node or distant metastases are rare (2%).
EPIRUBICIN IS NOT A SUBSTITUTE FOR
DOXORUBICIN IN ADVANCED SOFT
TISSUE SARCOMAS. FINAL DATA FROM
THE EORTC SOFT TISSUE AND BONE
SARCOMA GROUP
O. S. Nielsen, P. Dombernowsky, H. Mouridsen,
S. Daugaard, M. van Glabbeke,A. Kirkpatrick,
J.Verweij
EORTC STBSG, EORTC Data Centre, 1200 Brussels,
Belgium
Doxorubicin (dox) still appears to be one of the most
active drugs in the treatment of soft tissue sarcomas.
However, treatment duration is limited due to cumulative
cardiotoxicity. It is therefore important to test anthracy-
cline analogs.At present only few analogs have been evalu-
ated in studies with adequate number of patients. In two
studies of the EORTC STBSG we have tested whether
epirubicin (epi) is an alternative to standard dose dox in
the treatment of chemonaive patients with advanced soft
tissue sarcoma.The present report gives the ® nal results of
these studies. In the ® rst study 210 patients were rand-
omized to receive either dox or epi both at a dose of
75 mgm
± 2 given as bolus injection at 3-week intervals.
Median age was 54 years (18± 80 years) and Karnofsky
performance score 90 (50± 100). No difference in median
survival (41 weeks after dox vs 48 weeks after epi) and
duration of response (45 weeks after dox vs 77 weeks after
epi) was found. Of 167 evaluable patients 36 (22%) had an
objective tumor response (10 CR, 26 PR), and the response
rate was slightly in favour of dox (25% vs 18%) but at the
expense of more toxicity (leucopenia, alopecia, nausea/
vomiting). These data indicate that epi may be less toxic
than dox when administered in equimolar doses, and could
44 Abstractssuggest that increasing the epi dose may lead to a greater
antineoplastic effect with acceptable toxicity. Moreover,
cardiac toxicity may be related to the peak concentration of
the drug, and lower toxicity could therefore be expected
with fractionated as compared with bolus injections. In
view of this,we initiated our second study comparing single-
agent standard dose dox with that of two schedules of high
dose epi. A total of 334 patients received dox 75 mgm
± 2
day 1, epi 150 mgm
± 2 day 1 or epi 50 mgm
± 2 day
± 1, days 1,
2 and 3, all given as bolus injection at 3 week intervals.
Median age was 52 years (19± 70 years) andWHO perform-
ance score 1 (0± 2). Of 314 evaluable patients 45 (14%) had
an objective tumor response (8 CR, 35 PR).There were no
differences between the three groups.Median time to progres-
sion for the groups dox, epi-150 and epi-50 was 16, 14 and
12 weeks and median survival 45, 47 and 45 weeks,
respectively. Neither progression-free nor overall survival
differed between the three groups. After the 1st cycle of
therapy two patients died of infection and one due to
cardiovascular disease, all on epi. Both dose schedules of epi
were more myelotoxic than dox. Cardiotoxicity (‡ grade 3)
occurred in £ 2%. Based on these studies we can conclude,
that epi regardless of schedule and dose is not an alternative
to dox in the treatment of patients with advanced soft tissue
sarcomas. In addition, the results illustrate that the data from
small studiesof singleinstitutions should always be confirmed
by large multi-institutional studies before being taken for
granted.
EWING’S SARCOMA:
HYPERFRACTIONATED RADIOTHERAPY
WITH CONCURRENT CHEMOTHERAPY:
ACUTE TOXICITY. A PROSPECTIVE
SINGLE INSTITUTION STUDY
A. M. Cassoni, J. S.Whelan
The Middlesex Hospital, UCLH, London,W1N 8AA,
UK
Fifty-two patients with EWINGS/PNET were treated with
hyperfractionated radiotherapy with planned gaps, concur-
rent with intensive chemotherapy.Thirty were treated within
the EICESS study, eleven in the preceding E2 protocol. All
patients requiring radical radiotherapy as part of their initial
management were included.
Patients: Gender: male 30, female 22. Age (yrs): median
18, range 4± 54.
Site: Pelvis 19; lower limbs 20; upper limbs & shoulder
girdle 6; other 10.
Chemotherapy: IVAD2 16 patients; VAIA 17; EVAIA 14;
VIDE 1; CbEC 4.
Radiotherapy: adjuvant to surgery, 44.8 Gy/28#/29
daysÐ 15 pts; radiotherapy alone, 54.4 Gy/34# in either 3
blocks (46 days)Ð 16 pts or 2 blocks (35 days)Ð 21 pts.
Results: acute skin toxicity; grade 3 extremities,5 pts (19%)
but in all with perineum in ® eld (14 pts).
recall reaction; 2 pts.
treatment delivery; radiotherapyÐ delay of 5± 7 days in 3
pts (16%); chemotherapyÐ omission of anthracycline,
planned 5 pts, due to acute toxicity 3 pts, total 15%.
Conclusion: the majority of patients can be treated with
concurrent chemoradiation without modi® cation of the
chemotherapy regimen. Patients with perineum in the field
however may need modi® cation of overall radiotherapy
time or concurrent drugs. Late toxicity in spinal cord
remains a concern.
CLINICAL ASPECTS OF GIANT
LIPOSARCOMAS IN THE
RETROPERITONEUM
Th. van Dalen,A. N. van Geel, H. J. Hoekstra,
F. van Coevorden, A. H. Hennipman
Dutch Soft Tissue Sarcoma Group, Servaasbolwerk 14,
3512 NK Utretcht,The Netherlands
Background: Liposarcomatous tumours in the retroperito-
neal space are rare.The anatomic localization permits expan-
sion of these neoplasms with symptoms developing only at
a late stage of the disease. The resultant giant retroperito-
neal masses commonly lead to a defeatist attitude among
the treating surgeons. The case histories of patients with
ª giantº liposarcomas in the retroperitoneal space were
studied.
Methods: In a retrospective nation-wide study data were
collected on 45 patients treated in the Netherlands between
1988 and 1993 for primary giant retroperitoneal liposar-
comas. Patients with tumours weighing more than 1
kilogram or measuring more than 10 cm in diameter were
included. Median age was 53 years; there were 22 men
(49%).
Results: Symptoms were longstanding (>6 months) in
1/3 of the patients (16/45), common clinical features were:
palpable mass (60%), expanding abdomen (36%) and pain
(27%).The intra-abdominal mass was correctly diagnosed
as a retroperitoneal sarcoma in 30 patients (67%) prior to
de® nitive treatment. On operation half of the patients
(n=22) had tumours in the pararenal space, 8 had pelvical
liposarcomas and 7 had central tumours. Median diameter
of the tumour was 24 cm. and 29 tumours (64%) were of
low-grade malignancy. In 37 patients (82%) radical tumour
resection was feasible.
Median follow-up was 6 years, 5-yr. survival for all
patients was 59%. Irradical resection (5-yr. surv. 30%),
high malignancy grade (5-yr. surv. 25%) and pelvical
localisation (5-yr. surv. 38%) were unfavourable prognostic
factors.Tumourfree 5-year survival was 30% for all patients.
80% of the patients (25/31) in whom tumour recurred had
isolated locoregional recurrences. Following surgery for
relapses sarcoma 5-yr. survival was 39%.
Conclusions: Despite the large dimensions of ª giantº retro-
peritoneal liposarcomas radical resection is feasible in most
patients resulting in reasonable long-term survival. Aggres-
sive surgical therapy is justi® ed in patients with primary
retroperitoneal liposarcomas and patients with isolated loco-
regional relapse.
STROMAL SARCOMA OF THE STOMACH
M. Peiper,T. E. Langwieler, C. Bloechle,
C. Zornig
Universita È ts-Krankenhaus Hamburg-Eppendorg, 20249
Hamburg, Germany
Introduction: Gastric stromal sarcomas (GIST) represent
only about 1± 3% of all gastric malignancies.Patients gener-
ally lack speci® c symptoms. Despite advances in radiological
diagnostics and endoscopy including endosonography,
preoperative diagnosis of these tumors is rare. Because of
the rarity of these tumors there is a lack in understanding
their natural history and the best approach to their treat-
ment. Therefore, we analyzed retrospectively our series of
patients with this malignancy.
Methods:Twenty patients with GIST underwent surgery
at the University-Hospital of Hamburg-Eppendorf from
Abstracts 451979 to 1995. Resection quality was classi® ed according to
the UICC. In reviewing the histopathological slides tumor
grade (G1± 3) was determined according to the grading
system for soft tissue sarcomas of Enzinger and Weiss,
while classi® cation of tumors were performed according to
Fletcher and Franquemont.
Results: Symptoms were unspeci® c. Exact preoperative
diagnosis was difficult because of submu-cosal tumor
growth and was correctly performed in one patient. Opera-
tions varied from excision of the gastric wall to extended
gastrectomy (pancreas, spleen, partial liver resection). In
16 cases (80%), tumor could be resected with wide
margins (R0). In 4 cases, tumor was found at the resec-
tion line (R1). One patient died because of postoperative
complications. After a median follow-up of 69 months,
12 patients with R0 resections (including tumors with
poor differentiation or in® ltration of surrounding organs)
lived tumor-free, and two died due to other causes. All
four patients with R1 resections died because of tumor
disease within 40 months. There was a mean survival
time of 59 months and a 5-year-survival rate of 69%.
Discussion: Our series shows that not all gastric malignan-
cies have a dismal prognosis, but that gastric stromal
sarcomas have a favourable follow-up if resected with wide
margins at initial surgery.
SOFT TISSUE SARCOMA OF THE COLON
AND RECTUM
T. F. Langwieler, C. Zornig, M. Peiper
Dept. of Surgery, University Hospital
Hamburg-Eppendorf, 20246 Hamburg, Germany
Introduction: Soft tissue sarcoma (STS) of the colon and
rectum are rare mesenchymal neoplasm. Consequently,
analysis of small series of patients concerning tumor
characteristics as well as their treatment and how these
factors in¯ uence recurrence and patients survival is
particularly interesting.
Methods: Four consecutive patients with STS of colon
and rectum operated on at our institution between 1987
and 1994 were included. In this retrospective study we
analysed patient data, surgical therapy,tumor characteristics
as well as follow-up.
Results: There were 4 patients with a mean age of 49
(range 41± 58) years, 100% male. The STS were located
in the sigmoid (n=1), rectum (n=2) and colon descendens
(n=1). All tumors were resected with wide margins (R0).
Two tumors were highly differentiated (G1), 1 moderately
(G2) and 1 tumor was grade G3. Postoperative radiation
therapy and chemotherapy were administered in the
patient with the poorly differentiated tumor. 2 patients
developed tumor recurrence: in 1 patient 16 months after
complete resection peritoneal metastasis without local
recurrence occurred while the second patient developed
liver metastasis 9 months after complete tumor resection.
Two patients died after 18 and 29 months, respectively,
due to metastatic tumor disease. The other two
patients are without evidence of disease after 45 and 61
months.
Conclusion: The prognosis of sarcomas of colon and
rectum is poor. Complete surgical excision is the optimal
therapy. Nevertheless, adjuvant therapy might be favour-
able and we therefore consider this treatment in the future
even for patients with tumor resection.
PROGNOSTIC FACTORS IN
RETROPERITONAL SARCOMA. ANALYSIS
OF A SERIES OF 165 PATIENTS OF THE
FRENCH CANCER CENTER FEDERATION
(FNCLCC) SARCOMA GROUP
E. Sto È ckle*, F. X. Sastre, S. Bonvalot, G. Depadt,
P.Terrier, J. Cuisenier, J. M. Coindre*,
N. B. Bui*
*Institut Bergonie Â , 33076 Bordeaux Cedex, France
Objective:To analyse prognostic factors in a large multicen-
tric series of retroperitoneal sarcoma.
Methods: A series of 165 patients (pts) with primary
retroperitoneal sarcoma (retroSTS) registered in the
FNCLCC sarcoma group data was analyzed. Pts referred
for tumors recurrences were not considered. Median age
was 54 years (16± 82) and the sex-ratio was 0.9.The median
follow-up was 47 months. In only 6% of cases, the tumor
was <5 cm; 31% showed evidence of vasculonervous
involvement; 5% were N+ and 12% were M+ at referral.
MFH, liposarcoma and leiomyosarcoma represented 66%
of histological types; tumor grade was: G1 17%, G2 40%,
G3 43%. 150 pts had surgery, with complete tumor removal
in 65%. Radiotherapy was given to 92 pts and chemotherapy
to 77 pts. At the end of ® rst treatment, 118 pts (72%) were
considered as free of disease. Univariate and multivariate
analysisof prognostic factors for Complete Remission (CR),
Overall Survival (OS), Local Recurrence Free Interval
(LRFI), Metastatic Free Interval (MFI) and Disease Free
Interval (DFI) were done.
Results: 5-years OS was 45.7% and 5-year DFI was 28%,
with a 5-year LRFI of 31% and MFI of 66%. A disease-
free status at completion of treatment was correlated with
metastases at entry, tumor grade and vasculonervous
involvement. At multivariate analysis of the entire group,
OS was independently correlated with grade (p=.0007)
initial metastatic status (p=.005) and vasculonervous or
bone involvement (p=.04). For 145 pts M0 at entry, DFI
was correlated with tumor grade (p=.0016), complete
surgical excision (p=.0001) and radiotherapy (p=<.0001);
MFI was correlated with tumor grade (p=.0074) and a non
liposarcoma histology (p=.03); LRFI was correlated with
adjuvant radiotherapy (p<0.0001), complete excision
(p=0.0001) and tumor grade (p=0.005).
Conclusion: If surgery and a complete tumor removal
remains the cornerstone of the treatment in retroSTS,
radiotherapy may contribute to local control. Moreover,
although local control remains essential, a high risk of
metastatic disease was apparent.
EXPRESSION OF THE MET/HEPATOCYTE
GROWTH FACTOR RECEPTOR GENE IN
BENIGN MUSCULOSKELETAL TUMORS
Riccardo Ferracini, Marina Martano, Nicola
Baldini, Katia Scotlandi, Jay Wunder, Eric
Masterson
Institute for Cancer Research, St. Prov. 142, Km 3.95,
10060 Candiolo, Italy
Overexpression of the hepatocyte growth factor receptor
(Met/HGF receptor), a transmembrane tyrosine kinase
encoded by the Met proto-oncogene, has been involved in
transformation and invasive behaviour of human carcinomas
and sarcomas.We have previously found that bone sarcomas
express high levels of HGF receptor while in some cases
46 Abstractsthe ligand was co-expressed with the receptor, activating an
autocrine loop.In this study we analyzed 35 bioptic samples
of benign bone tumors for the expression of the Met proto-
oncogene.The lesions included osteoblastomas, chondrob-
lastomas, non ossifying ® bromas, giant cell tumors and
desmoplastic ® bromas of bone. The snap frozen samples
were tested by immunohistochemistry and Western blot-
ting with anti-Met antibodies or with RT-PCR for Met and
HGF mRNA. About 50% of all cases scored positive for
Met expression.Although non statistically relevant,we report
a trend of Met positivity in samples from recurrent or
locally aggressive lesions. Sporadic co-expression of the
Met receptor and ligand (HGF) was demonstrated. The
possible role of the Met receptor in the pathogenesis of
benign bone neoplasms suggests an early involvement of
the oncogene in sarcoma transformation.This is in contrast
to the biology of carcinomas where the Met oncogene is
ampli® ed as a late event in the neoplastic progression.
MANAGEMENT OF EXTRA-ABDOMINAL
DESMOID TUMOR
G. I. Castellarin, G. Barbanti-Bro Á dano,
G. Pignatti, N. Baldini
Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
This study includes a continuous series of 103 patients
with extra-abdominal desmoid tumor who were treated at
the same institution between 1970 and 1996. Twenty
patients were excluded from the analysis because of an
insufficient follow-up. Of the remaining 83 patients,35 had
a newly diagnosed lesion, whereas 48 presented with a
local recurrence after being surgically treated elsewhere.
Patients were treated only with surgery (n=63) or with
surgery plus radiation therapy (n=17) at doses ranging
3500 to 6600 cGy.Three patients did not undergo surgery,
and were excluded from the analysis.No patient died of the
disease, but 37 (46%) developed local recurrences. More
than three recurrences in 8 patients (10%). Overall, relapses
were not associated with age, sex,site,or tumor size,whereas
a trend toward a higher risk of recurrence was observed
when surgical margins were found to be inadequate on
pathologic examination. The relapse rate was similar in
patients treated only with surgery (28 cases, 45%) and
patients treated with surgery plus radiation therapy (7 cases,
41%). Among the 35 patients who were ® rst treated at our
institution, 13 (37%) developed a recurrence. Again, no
difference in the relapse rate was observed among patients
undergoing surgery plus radiation therapy (2/5 cases, 40%)
and patients treated only with surgery (11/30, 37%),whereas
inadequate (intralesional or marginal) surgical margins were
associated with a higher incidence of relapse (7/15, 47%)
compared to patients treated with a wide surgical excision
(7/20, 35%). These data con® rm that the best chances to
prevent the risk of local recurrence in extra-abdominal
desmoid tumor are offered by a careful preoperative staging
in order to obtain adequate surgical margins. Proper evalu-
ation of the ® nal specimen is mandatory to con® rm the
adequacy of surgery, although postoperative radiation
therapy does not appear to be able to prevent the risk of
local recurrence. Clinical observation should be considered
for slowly growing recurrences.
SUPPORT FOR LOCAL TREATMENT
MODALITIES IN PATIENTS WITH
AGGRESSIVE FIBROMATOSIS
R. Keus, F. van Coevorden
The Netherlands Cancer Institute, Antoni van
Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX
Amsterdam,The Netherlands
Background and Objectives:Aggressive ® bromatoses (desmoid
tumors) are rare soft tissue neoplasms with a typical clinical
behavior of frequent local recurrences and absence of distant
spread. Other characteristics of this disease are an age peak
between 30 and 40 years, female predominance often with
pregnancy associated abdominal wall lesions. Mesenteric
lesions are frequently seen in patients with an APC gene
mutation as in familial polyposis coli. Local treatment
modalities such as surgery and radiotherapy form the
mainstay of the management of these tumors. In patients
where local treatments are not feasible or failed, systemic
therapy by hormonal manipulation or chemotherapy
regimens is employed. The objective of this study was to
determine the efficacy of local treatment modalities and to
estimate the need for systemic treatment in our center.
Methods: A retrospective review of 105 patients (72
female, 33 male) in the period 1973 to 1997. Mean age was
33.1 years.Tumors were located in the head and neck in 11
patients, the extremeties in 50, abdominal wall in 24,
mesenteric in 6 and other trunk in 12.Treatment consisted
of surgery only in 21 patients, combined therapy with
surgery and radiotherapy in 62, radiotherapy only in 6,
isolated limb perfusion with Adriamycine and Melphalan
in 4, chemotherapy in 3. Observation after surgery elsewhere
was performed in 9 patients.
Results: Overall there was 86% local control at 5 years.
There was no difference in local control for primary vs.
recurrent lesions. Local control by treatment modality was
83%, 89%, 83% and 78% for surgery only, surgery and
radiotherapy, radiotherapy only and other treatments,
respectively. For the different tumor sites the were 100%,
81%, 88%, 67% and 100% in head and neck, extremities,
abdominal wall, mesenteric and other trunk, respectively.
No effect on local control of age, radiation ® eld size, radia-
tion dose was seen. The in¯ uence of surgical margin on
local control rate in the surgery only group was 92% vs.
50% and in the combined therapy group 100% vs. 85% for
patients with negative vs. positive surgical margins. Severe
complications were seen in 14 patients: radiation myelitis
1, nerve injury 4, vascularinjury 2, bone fracture 2, intestinal
® stula 3, chronic infection 1, post-irradiation sarcoma 1.
The outcome of chemotherapy in 3 primary and 3 recur-
rent lesions was in 1 CR, 2 PR, 1 NC and 2 PD.Tamoxifen
was applied in 4 patients with recurrent lesions resulting in
1 CR, 1 NC and 2 PD.
Conclusions:These results show that local treatment with
surgery and/or radiotherapy is effective in 86% of patients
with aggressive ® bromatosis. Only patients with extensive
or multiple lesions not suitable for local treatment, or those
who will be likely to suffer from unacceptable morbidity
from local treatment should be considered for future studies
of more effective systemic treatment.
MDR1 GENE EXPRESSION AND
OUTCOME IN OSTEOSARCOMA: A
PROSPECTIVE INTERNATIONAL
MULTICENTER STUDY
J. S.Wunder, R. S. Bell, I. L.Andrulis,A. M.
Davis, S. B. Bull, C. P. Beauchamp, E. U.
Conrad, R. J. Grimer, J. H. Healey, M. G. Rock
University Musculoskeletal Oncology Unit and Samuel
Lunenfeld Research Institute, Mount Sinai Hospital,
University of Toronto, Toronto, Canada M5G 1X5
Abstracts 47Chemotherapy resistance remains an important clinical
problem in osteosarcoma. This prospective, multicenter
study analysed the prognostic value of multidrug resistance
gene (MDR1) expression in patients with extremity,
non-metastatic, conventional, high grade osteosarcoma.
Between 1989 and 1994, 123 patients received adriamycin-
based multiagent neoadjuvant chemotherapy and locally
curative surgery, and were followed for a minimum of 24
months or until systemic recurrence. For each patient, a
sample from the primary tumor was analysed for MDR1
expression level using a quantitative polymerase chain
reaction-based assay.
MDR1 level was low in 44 tumors, intermediate in 39
tumors and high in 40. Of 123 patients, 46 (37%) relapsed
with metastases at a minimum 2-year follow-up. After
univariate analysis, only tumor size (p=0.0007) and
chemotherapy-induced tumor necrosis (p=0.031) were
associated with a higher risk of metastases. There was no
linear association between MDR1 expression level and
outcome (p=0.62). Surprisingly, patients with Intermediate
MDR1 levels had the best survival, compared to those with
either Low or High MDR1 expression. This relationship
remained unchanged even after adjusting for other vari-
ables. After multivariate analysis, tumor size was the only
signi® cant predictor of outcome (p=0.004). As well, no
relationship existed between MDR1 level and
chemotherapy-induced tumor necrosis.
These results suggest that there is no simple linear
relationship between MDR1 gene expression and systemic
relapse in osteosarcoma. Patients whose tumors had High
MDR1 expression did worse than those with Intermediate
levels. On the other hand, Intermediate levels predicted for
a better outcome than Low levels. If MDR1 expression is
important in osteosarcoma, other mechanisms may play a
more critical role. Studies using immunohistochemistry
(IHC) have suggested that elevated P-glycoprotein levels
are associated with a poor outcome. These results are in
contrast to our data which show that patients whose tumors
had low MDR1 levels had a worse prognosis.To help clarify
this, we are presently evaluating a subset of tumors in our
study of P-glycoprotein status by IHC. Mutation of the
p53 gene might be another potential mechanism affecting
outcome. Mutant p53 has been suggested to cause tumor
drug resistance, and may also stimulate the MDR1
promoter, while wild-type p53 may act as a repressor.The
interaction between these two genes may be important,
and is also being investigated.
COMBINED THERAPY FOR
RETROPERITONEAL SARCOMA (RPS):
RADIATION DOSE ESCALATION WITH
POSTOPERATIVE BRACHYTHERAPY (BT)
C. J. Swallow, C. N. Catton, B. O’Sullivan,
J. Couture, R. A. Kandel
The Sarcoma Site Group, University of Toronto, Canada
Introduction:The anatomical constraints of the retroperito-
neal space make adequate resection and effective irradia-
tion of RPS particularly challenging,and treatment outcome
is far worse than for sarcomas at other sites.We have recently
implemented a new treatment protocol for RPS which
involves aggressive en bloc total gross resection combined
with escalated dose radiotherapy to the tumor bed using
external beam radiotherapy (RT) and postoperative BT.
Treatment outcome has been studied prospectively.
Methods: Over an 18 month period, 32 patients with
primary or recurrent RPS were referred to our center. Of
these, 18 were eligible for curative therapy with combined
surgery and radiation. Sixteen patients completed all phases
of therapy, while 2 who developed metastases during RT
were taken off protocol. Sixteen patients had a total gross
resection. Fourteen were treated with RT and BT, and 2
patients treated for recurrence after prior RT had BT only.
RT was given preoperatively (n=12) or postoperatively
(n=2) with a parallel pair to a dose of 45 or 50 Gy in 25
fractions over 5 weeks. Planar pulsed dose rate BT was
administered postoperatively at 0.5 Gy/hr prescribed at
0.5 cm through temporary catheters implanted intraopera-
tively. The median total combined dose to the tumor bed
was 70 (60± 77) Gy. Outcome was assessed prospectively
with toxicity scored according to the RTOG system.
Results: Of the 16 patients who completed all phases of
therapy, 9 had a primary RPS and 7 presented following
1± 3 recurrences. Median tumor diameter along the largest
axis was 12 (4± 28) cm. All patients had a total gross resec-
tion. Adjacent structures completely or partially resected
included psoas/iliacus (63%), large bowel (63%), kidney/
adrenal (63%), chest wall/diaphragm (31%), liver (31%),
pancreas (19%), stomach (19%), spleen (19%), and small
bowel (12%). The median area implanted was 68 cm2
(30± 96 cm
2).
Median postoperative follow-up is 14 (4± 24) months.
The highest acute RTOG score after RT was 2, in 6 patients.
After BT, 5 patients required parenteral nutritional support
for transient duodenitis or enteritis and had an acute score
of 3. One patient developed respiratory complications
requiring early termination of BT and transfer to the ICU,
and 1 patient died of complications following aspiration
pneumonia. In 13 evaluable patients, the late toxicity score
is 0 in 10, and 3 in 2. At a median of 14 months, one
patient has failed with out-of-® eld mesenteric seeding, while
12 patients remain disease-free.
Summary: This study demonstrates the feasibility of
combining an aggressive resection with high doses of radia-
tion to the tumor bed for primary or recurrent RPS. Resec-
tion of involved adjacent structures produced a resection
rate of 100%. Treatment-related mortality was 6%.
Postoperative complications and acute radiation toxicity
were manageable in the majority of cases. Preoperative RT
was very well tolerated, and the late radiation toxicity from
combined RT and BT was signi® cant but acceptable. The
efficacy of this approach will be tested in a phase II trial.
A BIOLOGICALLY RELEVANT MODEL OF
OSTEOSARCOMA WITH SPONTANEOUS
PULMONARY METASTASES
C. Khanna, L. Helman
Pediatric Oncology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892,
USA
Osteosarcoma (OSA) is the most common primary tumor
of bone. Despite successful control of the primary tumor
and adjuvant chemotherapy, relapse of OSA in the lungs
occurs in 30% of patients within 5 years.A relevant animal
model for OSA is needed to evaluate novel treatments and
to identify key determinants for lung metastases.The objec-
tive of this work was to develop a model of OSA in an
immunocompetant host, with primary tumor growth at
orthotopic sites, spontaneous pulmonary metastases and
variants differing in pulmonary metastatic potential.
Hypothesis generation in these studies was based on the
premise that tumor growth and metastasis are in¯ uenced
by the host, the microenvironment and the tumor.
Murine OSA cell lines (K-7 and K-12), derived from a
spontaneous murine OSA (Schmidt et al), were delivered
48 Abstractsat ectopic and orthotopic sites to 4 wk female balb/c mice.
Sites for tumor cell line (or enzymatically digested tumor
tissue) injection included subcutaneous, intramuscular
(IM), intratibial, and intrafemoral. Sites for tumor frag-
ment implantation included proximal tibial bone ¯ aps or
cranial tibial muscle ¯ aps. Endpoints included primary
tumor growth, bone invasion, radiographic change and
incidence of lung metastases. The in¯ uence of tumor-
bearing-limb amputation on lung metastases was studied.
Lung metastases from K-7 tumors were surgically
re-implanted to tibial bone ¯ aps. Repeating this lung to
bone passage two times, yielded the K-7M2 variant.
Features of K-7M2 were evaluated as above.
From the experimental variables studied the optimal
model system consisted of surgical implantation of tumor
tissue at a tibial muscle ¯ ap or IM injection of enzymati-
cally digested tumor followed by amputation of limbs
bearing 1 cm tumors. using this model system, K-7 tumors
developed in 12 days in 93% of mice, growing to 1 cm in
19 days. K-12 tumors developed in 12 days in 87% of
mice, growing to 1 cm in 26 days. After amputation
pulmonary metastases occurred in 100% of K-7 mice
compared to 58% of K-12 mice. The median survival for
K-7 mice was shorter than K-12 (61 days compared to 138
days; p<0.01. K-7M2 had primary tumor growth similar to
K-7, but earlier death from lung metastases (median survival
48 days).
This biologically relevant OSA model will offer a valu-
able tool for the evaluation of novel OSA treatment strate-
gies and will improve our understanding of OSA metastases.
This model is characterized by orthotopic primary tumor
growth in an immunocompetant animal, spontaneous lung
metastases, and variants with a pulmonary metastatic
gradient from most aggressive to least aggressive (K-7M2,
K-7, K-12). The osteosarcoma model developed will offer
a valuable tool for the evaluation of novel treatment strate-
gies for osteosarcoma and for the examination of
determinants of osteosarcoma metastases. Studies are
underway to identify genetic determinants that may account
for differences in the metastatic potential of the K-7, K-12,
and K-7M2 models. Results of this model characterization
and the ongoing genetic studies will be presented.
GROWTH INHIBITION OF
LEIOMYOSARCOMA INVIVO USING AN
ADENOVIRUS OVEREXPRESSING THE
TRANSCRIPTION FACTOR E2F-1
N. Hetrakul,A.Abramanian,T.-J. Liu,
M.Wilson-Heiner,W. Xia, N. Mirza, D.Yu,
R. Pollock, B. Feig, P. Pisters, K. Hunt
The University of Texas M.D.Anderson Cancer Center,
Houston,Texas 77030, USA
We have previously shown that overexpression of the
transcription factor E2F-1 results in apoptotic cell death in
leiomyosarcoma cells lines in vitro.This cell death appears
to be independent of the p53 status of the cells. We
hypothesized that overexpression of E2F-1 in established
tumors would result in growth inhibition in vivo.
Methods: The leiomyosarcoma cell line SKLMS-1 was
injected into the ¯ ank of Balb/c nu/nu mice at 5 3 10
6 cells
per animal. Once tumors reached 5 mm size, tumors were
injected with PBS (6 mice), a recombinant adenovirus
expressing the Luciferase reporter gene (Ad5Luc; 6 mice)
or a recombinant adenovirus expressing E2F-1 (Ad5E2F;
7 mice). Ad5Luc and Ad5E2F were injected at a dose of 2
3 10
9 pfu every other day for a total of 13 injections.
Tumor growth was measured in 3 dimensions and recorded
as tumor volume (mm
3). Mice were sacri® ced when tumors
reached 20 mm in size and assessed for apoptosis using in
situ TUNEL assay. E2F expression was evaluated using
immunohistochemistry.
Results: We noted marked reduction in tumor growth in
the Ad5E2F treated tumors over controls (PBS and
Ad5Luc). Please see graph below.
Tumor growth in the Ad5E2F treated animals was
signi® cantly reduced as compared to Ad5Luc treated or
PBS treated controls (P=<0.0001) by ANOVA.There was
complete tumor regression in two animals. In situTUNEL
demonstrated apoptosis in Ad5E2F treated tumors in
20± 30% of cells per high power ® eld examined. Overex-
presssion of E2F was con® rmed using immunohistochem-
istry and was predominantly nuclear.
Conclusions: Adenovirus mediated overexpression of
E2F-1 leads to nuclear localization of E2F-1 with resultant
apoptotic cell death in leiomyosarcoma. In vivo gene therapy
utilizing E2F-1 results in signi® cant growth inhibition and
may prove to be a useful strategy in the clinical manage-
ment of leiomyosarcoma.
PREOPERATIVE TAILORED RADIATION
THERAPY FOR ADVANCED
RETROPERITONEAL SOFT TISSUE
SARCOMAS. A FEASIBILITY STUDY
Alessandro Gronchi,Alberto Azzarelli,
Marcello Zanini, Lorenza Gandola, Susanna
Fissi, Paolo Casali, Rossella Bertulli
Istituto Nazionale Tumori,ViaVenezian 1, 20133
Milano, Italy
Purpose: Retroperitoneal soft tissue sarcomas (RSTS) are
generally large lesions,often recurrent and involving viscera,
which are difficult to be treated properly with surgery. For
postoperative radiation therapy (RT) to be effective, one
should employ doses and ® elds which are unfeasible. In an
effort to improve results, we decided to assess the feasibility
of an approach including preoperative RT. In this way, RT
® elds can be tailored to the lesion, and the lesion itself
works as a spacer able to protect viscera, while surgery
could take advantage from a response to RT.
Materials and methods: Since September ’96 to December
’97, 12 consecutive patients with extensive recurrent RSTS
were treated with preoperative RT up to 50 Gy. Surgery
was scheduled between the 30th and 60th day after the end
of RT. The ® elds of RT were designed upon an isodose
simulation CT scan, especially targeted to the portions of
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to be achieved, also considering whether colectomy or
nefrectomy would have been performed or not. The end
points were the overall feasibility of the treatment program,
the intraop. and postop. complications, the pathologic
response rate and the local control.
Results: Twelve pts. were treated: 8 liposa. (3 G1), 3
leiomiosa. (2 G1), 1 NOS sarcoma. One pt. received only
32 Gy for gastrointestinal intolerance. Radiological response
was minimal in all pts. All the patients underwent surgery
32± 46 days later. In ten patients, the lesion was removed
completely. Resections were extended to viscera, with 4
nefrectomies and 6 colectomies. No major surgical difficul-
ties were encountered, and the lesions always appeared well
demarcated. No surgical contamination did occur. Postop-
eratively, 4 of 6 colectomies were complicated by anasto-
motic ® stulas, and two required colostomy. One pt. died
three months later due to abdominal complications. One
pt. died due to disease recurrence. One pt. was reoperated
for disease recurrence 10 mos later. Pathologic response
was always consistent with post-RT alterations. Up to now
(follow-up range 8± 20 mos), all the other seven patients are
alive with no evidence of disease.
Conclusion: Preoperative RT is feasible in RSTS. In the
case a large bowel anastomosis is required, precautional
colostomy or ileostomy should be considered.
HIGH-DOSE IFOSFAMIDE AND
DOXORUBICIN (HDI-DX) IN ADVANCED
PREVIOUSLY UNTREATED SOFT TISSUE
SARCOMA (STS) PATIENTS. A PHASE II
STUDY OF THE SPANISH GROUP FOR
RESEARCH ON SARCOMAS (GEIS)
A. Lo Â pez-Pousa, J. Montalar, J. M. Buesa,
J. Maurel, J. Martin, J. Cassinello, I. Sevilla,
R. De las Pen Ä as, J. Cruz, C. Balana, J. GarcõÂ a del
Muro,A. Povedo
Spanish Group for Research on Sarcomas, Hospital de
Sant Pau, Avda Padre Claret 167, 08025 Barcelona,
Spain
Introduction: Doxorubicin (DX) and high-dose Ifosfamide
(HDI) are two active drugs in the treatment of STS with a
similar response rate.We are performing a phase II trial in
® rst line treatment with HDI-DX (scalating dose of HDI),
in order to evaluate the activity and toxicity of this regime.
Material and methods: Since Jul 97 we have included 54
previously untreated advanced STS pts in a trial with
HDI-DX, with a ® xed dose of DX 50 mg/m
2 and a
continuous infusion of HDI, starting at 12 g/m
2 and
scalating dose to 13 and 14 g/m
2 (2 g/m
2 in 2-hours infu-
sion d1, followed by 2 g/m
2/day d1 to d5± 6), in absence of
any grade IV toxicity or neutropenic fever, per cycle in each
patient. Otherwise a dose reduction to 10 g/m
2 has been
allowed. GM-CSF (Leucomax (Schering-Plough) 5 m g/Kg/
day 3 7 days has been administered after the end of each
cycle of chemotherapy.
Thirty-® ve pts are already evaluable: 16 male, 19 female;
median age 55 (27± 65) years. Performance status: WHO
grade 0± 13; 1± 14; 2± 8 pts. Histology: leiomiosarcoma 9,
malignant ® brous histiocitoma 5, synovial 3, liposarcoma
3, ® brosarcoma 3, neurogenic 3, mixed mu È llerian 2, others
7.Target tumor location: non-resectable primary or recur-
rence 18 (exclusively 10), lung 16, nodal 2, liver 2, soft
tissue 1, peritoneal 1 and bone 1. Histologic grade: 1± 6;
2± 9; 3± 17 pts.
Results:We have already administered 87 evaluable cycles
(cy), median 2 (range 1± 5). Dose intensity of HDI has
been 2.80 (1.7± 3.5) g/m
2/week. Dose of HDI per cycle has
been: 12 g/m
2 in 51 cy, 13 g/m
2 in 12 cy, 14 g/m
2 in 5 cy
and 10 g/m
2 (reduction dose) in 19 cy.
Haematologic toxicity (grade 3± 4 CALBGÐ % cy): Hbne
17%, Leuc 13% G3, 37% G4; Gran 9% G3, 41% G4; Plat
14% G3, 12% G4.
Non-Haematologic toxicity (grade 3± 4 CALBGÐ % cy):
Nausea 13%; Vom 14%; Stomatitis 9% G3; Hematuria 1%
Neurocortical 5% G3, moderate somnolence/blurred vision
9%; Infection 18% G3, 5% G4; Asthenia 19% G3, 2% G4;
Anorexia 15%; Cardiac 3.5% G3. Thirteen pts have
presented neutropenic fever in 20 cy (23%).There was one
toxic death due to a septic shock after the ® rst cycle of
chemotherapy. RBC transfusions were required in 22% cy
and plt transfusion in 5% cy. Objective activity: 8 PR, 7
SD, 5 PD, 8 NE in 28 evaluable pts.
Conclusions: HDI-DX is an active regime in adult STS.
The impact of haematological toxicity may limit the use of
this schedule and it is too early to evaluate the cardiac and
neurological toxicity.
HIGH DOSE CHEMOTHERAPY FOR SOFT
TISSUE EWING’S SARCOMAS
R. E. Hough, S. Browne, L. M. El-Helw,
R. E. Coleman, M. H. Robinson, P. C. Lorigan
Yorkshire Cancer Research Department of Clinical
Oncology,Weston Park Hospital, Sheffield S10 2JS, UK
Soft tissue Ewing’s sarcoma, peripheral neuroectodermal
tumours (PNET) and Askin’s tumours are small round
blue cell tumours which characteristically have a reciprocal
translocation between chromosome 11 and 22. As with
other rare tumours, clinical trial data on the optimal
management of these patients is limited. We review the
results of 6 patients treated with conventional chemotherapy
and compared these to 9 patients treated with standard
induction regimens followed by high dose chemotherapy
(HDC).
6 patients (1 female, 5 male) received standard
chemotherapy with IVAD (or similar regimen). Mean age
at presentation was 23 years (range 16± 33 years). 2 had
localised disease, 2 locally advanced and 2 metastatic
disease. Additional radical radiotherapy was given to 5
patients and surgery was performed in the other. 4 patients
have died at a median time of 284 days. Survival in the 2
remaining patients is 1947 and 2006 days.
9 patients received IVAD (7 patients) or EVAIA (2
patients) induction chemotherapy. Mean age at presenta-
tion was 26 years (range 17± 39 years). 3 had locally
advanced disease with the remainder having metastatic
disease. Complete response (CR) was achieved in 2 patients
and a good partial response (PR) was seen in all others.
HDC in all patients was with Etoposide, Carboplatin and
Melphalan and a further 3 CR were achieved. Additional
radical radiotherapy was given to 6 patients. 6 patients have
died after a median interval of 421 days.3 patients are alive
and in remission at 417, 666 and 884 days.
Soft tissue Ewing’s sarcoma often responds to
conventional chemotherapy but tends to relapse, and the
long term prognosis is poor. HDC may offer some survival
advantage but multi-centre clinical trials of this and newer
strategies will be vital in improving the outlook for these
patients.
50 AbstractsSUCCESSFUL PHASE II TRIAL OF
ETOPOSIDE AND HIGH DOSE
IFOSFAMIDE IN NEWLY DIAGNOSED
METASTATIC OSTEOSARCOMA:
PRELIMINARY REPORT. A PEDIATRIC
ONCOLOGY GROUP TRIAL (POG)
A. M. Goorin, P. Gieser,W. Ferguson, M. Harris,
M. Link, M. Gebhardt, G. P. Siegal,
R. C. Shamberger, M. Bernstein, C. Schwartz,
H. Berrey, H. E. Grier
Pediatric Oncology Group, Chicago, IL, USA
Patients with metastatic osteosarcoma (MOS) at presenta-
tion have a long term survival of <30% (POG 9259). The
use of the most active agents in MOS have all produced
tumor regression in only 20± 30% of patients with MOS.
More effective chemotherapy to treat MOS is needed. An
MTD of 500 mg/M
2 of etoposide (VP), and 17.5 gms/M
2
of ifosfamide (IFOS) was determined in POG 9170 for
relapsed MOS (cumulative cisplatin dose £ 300 mg/M
2).
That trial had a response rate (RR) of 6 of 13.Thus a phase
II trial was initiated.The objective was to estimate the RR
and de® ne toxicity of VP, IFOS, and G-CSF in newly
diagnosed MOS.The study was closed September 15, 1997
having reached its accrual goal. A total of 43 patients were
registered. Two patients were ineligible; 2 were not evalu-
able; and 39 were evaluable for response. Patients received
infusions of 100 mg/M
2/day of VP over 1 hour followed by
3.5 gr/M
2/day of IFOS over 4 hours for 5 days total.G-CSF,
was began on day 6.This was repeated in 3 weeks.Response
was determined at week 6. Eligibility included: age £ 30
years, biopsy proven newly diagnosed, previously untreated
MOS, and ECOG performance status £ 2.Twenty-eight of
41 (68%) have metastatic sites only in the lung and 13
(32%) have synchronous MOS with metastatic sites in
other bones.Toxicity was evaluated in 38.The most serious
toxicities are; grade 5 sepsis (death) in 1; grade 3 and 4
sepsis in 6; grade 3 and 4 infections (non-sepsis) in an
additional 5. One patient died of congestive heart failure
(CHF), and a second patient had grade 1 CHF. Grade 4
neutropenia occurred in 30 and Grade 4 thrombocyto-
penia in 18. Grade 3 Fanconi’s Syndrome developed in 4
and one additional patient had grade 4 Fanconi’s. Response
information is available on 38 patients.Three had CR’s; 20
PR’s; 3 MR’s; 10 NR; 2 PD.The RR (CR + PR) is 61% ±
8% (SE). We conclude that the combination of VP and
high dose IFOS are very effective induction treatment for
high risk MOS despite signi® cant associated myelosuppres-
sion sometimes complicated by infection, and renal toxicity
requiring electrolyte replacement.
PEGYLATED LIPOSOMAL DOXORUBICIN
(DOXIL¿ ) IN REFRACTORY SARCOMA
K. M. Skubitz
University of Minnesota Medical School, Minneapolis,
MN 55455, USA
There is interest in administering chemotherapy drugs in
liposomes as a means of altering the therapeutic index of
the drug. Liposomal doxorubicin is of particular interest
since less cardiotoxicity has been observed, and there may
be greater anti-tumor efficacy. Pegylated-liposomal doxoru-
bicin (Doxil¿ ) is a unique form of liposomal doxorubicin
in which the liposomes are coated with methoxypoly
(ethylene glycol). The polymer confers useful properties
including a diminished uptake by the reticuloendothelial
system, leading to a much longer half-life in blood (~ 50± 60
hours), and a different toxicity pro® le than non-pegylated
liposomes.We are performing a phase II study of Doxil¿
in refractory sarcoma. The patient population consists of
patients that have failed doxorubicin, DTIC, ifosfamide,
VP-16, and in some cases additional chemotherapy. The
initial dose per course is 55 mg/m
2 every four weeks. Dose
modi® cation based on mucositis and hand-foot syndrome
(the main limiting toxicities) is performed following an
algorithm that modi® es both dose and interval between
treatments.Treatment was generally well tolerated. Of the
® rst 29 evaluable patients, there were: 5 osteosarcomas, 7
gastrointestinal leiomyosarcomas, and 17 other soft tissue
sarcomas. Eight had stable disease for 14, 7, 6, 3, 3, 3+, 2+,
and 2+, months; 1 a mixed response, 3 a minor response
for 3+, 4, and 9 months, and 2 a partial response
(maintained for 5, and 24+ months). These data suggest
that pegylated-liposomal doxorubicin has signi® cant activity
in refractory sarcoma.
REPAIR OF RADIATION-INDUCED DNA
DOUBLE STRAND BREAKS IN HUMAN
FIBROBLASTS
J.Aronowitz, B. Nevaldine, P. Hahn
State University of NewYork Health Science Center,
Syracuse, NY 13204, USA
Introduction: Little is known regarding the repair kinetics of
radiation-induced DNA double strand breaks (DNAdsb),
especially in normal tissue. With increasing interest in
assaying normal tissue radiosensitivity, as well as in opti-
mizing time-dose-fractionation schemes to maximize
therapeutic ratio, we endeavored to develop techniques to
quantify normal ® broblast repair kinetics.
Materials and methods: Non-transformed cultured ® brob-
lasts from a normal human subject were studied. It was
determined that terminal differentiation occurred after 18
passages. Utilizing a system based on pulsed-® eld gel elec-
trophoresis, we measured repair kinetics of cohorts of cells
from the 7th and 15th passages following irradiation with
7.5 Gy.
Results: Approximately 50% of DNAdsb were repaired
within minutes (fast repair), an additional 30% before the
end of the ® rst hour, and most of the remaining breaks
were repaired during the second and third hours.TheT
½ of
slow repair during the ® rst hour was 40 minutes. There
were no appreciable differences in the repair kinetics
between ® broblasts from early (7th) and late (15th)
passages.
Conclusion: The repair kinetics of DNAdsb in human
® broblasts can be determined. In this culture of normal
human ® broblasts, repair kinetics were not altered by the
age in culture.
PHASE II TRIAL OF ONCONASE¾ (ONC) IN
PATIENTS WITH ADVANCED MALIGNANT
MESOTHELIOMA (MM): ANALYSIS OF
SURVIVAL
R. N.Taub, M. L. Keohan, R. L. Fine,
J. Constanzi, Z. Darzynkiewicz, H. Chun,
A. Mittelman,T. Panella, S. McCachren,
C. Puccio, K. Shogen, S. M. Mikulski
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RLF], Lone Star Oncology, Austin,TX [JC], NewYork
Medical College,Valhalla, NY [ZD, HC, AM, CP],
Thompson Cancer Survival Center, Knoxville,TN [TP,
SM], Alfacell Corporation, Bloom® eld, NJ [KS,
SMM], USA
Systemic therapy for advanced, unresectable MM remains
unsatisfactory. No single or combination drug regimen has
been shown to prolong survival.We have conducted a clinical
phase II trial of ONC (previously known as P-30 protein),
a novel ribonuclease isolated from the eggs of the leopard
frog (Rana pipiens), in patients with advanced unresectable
MM. ONC had previously demonstrated in vitro activity
against human primary mesothelioma cell cultures. In this
multicenter open label trial, single-agent ONC was given at
a dose of 480 m g/m
2 I.V. weekly (as a 30-min infusion) to
105 enrolled patients (85M:20F, performance status 0± 2)
until disease progression or intolerable toxicity. 92 pts had
prior surgery (none had complete resection), 17 prior
radiotherapy, 39 prior chemotherapy. Involvement of the
pleura/lung was noted in 97 pts, including 17 with
pleural+peritoneal disease; 8 pts had peritoneal disease
only. 38 pts had regional lymph node involvement, and 33
had distant metastasis. Toxicities were reversible and
manageable. 16 pts were terminated from study due to
toxicity, 4 of which for grade 4 toxicities.As of 6/15/98, the
estimated Kaplan-Meier median survival times (MSTs) for
the intent-to-treat group (105 pts) was 5.8 months (1 and
2 year survival,34.3% and 20.0%). Patients with confirmed
epithelioid histology (50/105) fared better (MST 9.6
months, 1 and 2 year survival, 42% and 23.4%) than pts
with pure sarcomatoid histology (8/105 pts, MST 1.9
months, 1 year survival 12.5%). Age under 50 (17/105 pts,
MST 19.8 months), female sex (20/105 pts, MST 11.4
months) and performance status of 0 (29/105 pts, MST
18.4 months) were favorable criteria for survival. Our 1
and 2 year survival data compared favorably with those of
analagous prognostic groups as de® ned by the Cancer and
Leukemia Group B (CALGB) among 337 pts treated by
CALGB with different Phase II agents or regimens over a
10-year period. Our data indicate that ONC may be active
in selected patients with MM. A randomized Phase III trial
of ONC v. doxorubicin is now in progress.
BLOCKAGE OF INSULIN-LIKE GROWTH
FACTOR I-RECEPTOR IN EWING’S
SARCOMA: A PROMISING BASIS FOR
INNOVATIVE THERAPY
K. Scotlandi, S. Benini, M. Serra,
M. C. Manara, P. Picci, N. Baldini
Laboratory of Oncology Research, Istituti Ortopedici
Rizzoli, 40136 Bologna, Italy
Innovative treatment modalities are needed for Ewing’s
sarcoma (ES), a neoplasm with a disappointingly low
survival rate despite the use of aggressive multimodal
therapeutic approaches.We have previously shown the exist-
ence and the pathogenetic relevance of an autocrine loop,
mediated by the insulin-like growth factor-I receptor (IGF-
IR), that is crucial for survival and proliferation of ES cells
in vitro. In this study, we report that the IGF-IR-blocking
monoclonal antibody a IR3 may also signi® cantly inhibit
ES cell growth in vivo. In particular, in almost one-half of
animals tested, blockage of IGF-IR by a IR3 induced a
complete regression of tumors developing after s.c.inocula-
tion of ES cells, suggesting the value of IGF-IR as a specific
target for novel therapeutic strategies.Also suramin, a drug
that is able to interfere with growth factor binding to their
receptors, inhibited both the tumorigenic and the metastatic
ability of ES cells, therefore offering as a promising agent
to be combined with conventional cytotoxic drugs for the
design of more effective therapeutic regimens. Moreover,
both a IR3 and suramin treatment increased the antitumor
in vitro effects of adriamycin and vincristine, two
conventional chemotherapeutic drugs with a leader action
on ES, producing additive growth suppression of ES cell
lines. This result was obtained both by simultaneous and
sequential treatments.Analysis of the proliferation rate and
of apoptosis revealed that a IR3 antibody did not
substantially affect the blockage of cell cycle in G2/M phase
induced by adriamycin, whereas it signi® cantly enhanced
the induction of apoptosis. A synergistic and dose-
dependent effect was indeed observed with regard to the
percentage of apoptotic nuclei after treatment with a IR3
and adriamycin, indicating that the speci® c blockage of
IGF-IR deprives ES cells of an important tools preventing
apoptosis induced by chemotherapeutic agents. In conclu-
sion, we showed that the blockage of IGF-IR by neutral-
izing antibody or by suramin may signi® cantly inhibit the
growth of ES cells both in vitro and in vivo, and that this
treatment strategy greatly potentiates the antitumor activity
of conventional chemotherapeutic drugs.
METASTASECTOMY AND
CHEMOTHERAPY FOR LUNG
METASTASES FROM SOFT TISSUE
SARCOMA. A RANDOMIZED PHASE III
STUDY
K. S. Hall
1,A. N.Van Geel
2, R. Blum
3,
T.Alvega Ê rd
1
1Scandinavian sarcoma group (SSG),
2European
organization for research and treatment of cancer
(EORTC),
3Eastern cooperative oncology group
(ECOG), Oslo, Norway
Soft-tissue sarcoma tumours account for approximately 1%
of all malignancies. Although most patients present with
apparently localised disease about 50% will die from
subsequent metastases. In 70% of all cases metastatic
disease involves the lungs only.This observation has led to
the concept of surgical treatment for lung metastases. By
proper selection a 5-year survival of about 40% can be
obtained by metastasectomyalone.The present study aims
to assess if preoperative chemotherapy with Doxorubicin
and Ifosfamide improves survival of patients scheduled for
metastasectomy for pulmonary metastases.
The study was initiated in April 1996 as an intergroup
study between SSG, EORTC and ECOG. Patients
undergoing radical metastasectomy of 5 or fewer lung
metastases will be randomized to receive
pre-metastasectomy chemotherapy (treatment #1) or no
chemotherapy (treatment #2). Patients with treatment #1
will receive 3 chemotherapy cycles before and 2 cycles after
metastasectomy provided if there is either a complete or
partial response on CT scan or if there is a histological
response grade III or IV. For grade I tumours (no necrosis)
the patient does not continue to post-operative
chemotherapy. Each participating institution has to select
one of the two proposed chemotherapy regimen (standard:
Doxorubicin 50 mg/m
2+Ifosfamide 5 g/m
2 or intensi® ed:
Doxorubicin 75 mg/m
2+Ifosfamide
5 g/m
2+GCSF:granulocyte-macrophage colony-stimulating
factor).
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end-points are disease free survival and side effects. To
detect an improvement of 15% in the 3-year overall survival,
340 patients need to be included in the study.Final analysis
will be performed after observation of 190 deaths.
Study status: So far 5 institutions from 2 cooperative
groups have entered 12 patients. A total of 12 EORTC
investigators have obtained approval from their local ethical
committee, and 3 additional centers have submitted the
protocol for approval. From SSG a total of 16 centers have
con® rmed their interest in participation of the study.The
ECOG has recently joined this intergroup protocol, and
the SWOG is considering its participation.
Conclusions:The major problem of this study has been a
slow inclusion rate. As concluded in an intergroup meeting
last April 1998 in Leuven arranged by EORTC SoftTissue
and Bone Sarcoma Group it is important that thoracic
surgeons are informed of this protocol since they often see
these patients primarily.Currently work is ongoing to recruit
the participation of additional centers (SWOG and MSK).
p53 INHIBITS REPAIR OF DNA DAMAGE
FROM g -IRRADIATION IN HUMAN
SARCOMA CELLS
M. Milas, F.Ali-Osman, O.Akande, D.Yu,
R. E. Pollock
The University of Texas M.D.Anderson Cancer Center,
Houston,Texas 77030, USA
Introduction: Mutations of the p53 tumor suppressor gene
are the most frequent genetic abnormality in soft tissue
sarcomas, a group of tumors frequently resistant to radia-
tion. We have previously shown that wild type (wt) p53
status enhances radiosensitivity of human leiomyosarcoma
cells. Consequently, we investigated the mechanisms by
which wt p53 mediates this improved radioresponse.
Methods: All experiments were conducted using a human
leiomyosarcoma cell line SKLMS, with a missense p53
mutation at codon 245, and derived stable transfectants
expressing constitutive wt p53 (SKp53-2, SKp53-3), a
temperature-sensitive p53 mutant (SKAla-1), or a
neomycin-resistant marker gene (SKneo). After 0, 5, or 10
Gy irradiation, distribution of cell cycle phases was
determined by ¯ ow cytometry, and apoptosis rate by
TUNEL assay. DNA damage and repair following irradia-
tion at these doses was quanti® ed by a PCR-based assay
which displays decreased ampli® cation product when there
is a damaged DNA template that cannot bind or extend
PCR primers. In this case,the DNA template was an actively
transcribed gene, glutathione-S-transferase p (GST-p ),
whose gene product catalyzes glutathione conjugation to
various electrophilic compounds including both carcinogens
and anticancer agents. Damage to the GST-p gene presum-
ably re¯ ects the potential damage to other actively
transcribed genes in this cell line. Cells were assayed at
various intervals between 0 min to 24 hrs after irradiation.
Results:There was minimal G1 and G2/M cell cycle arrest
after irradiation in these cell lines. However, both the wt
p53 containing radiosensitive cells (SKp53-2, SKp53-3)
and mutant p53 radioresistant cells (SKLMS, SKneo)
showed similar distribution of cell cycle phases after radia-
tion. None of the cell lines had signi® cant apoptosis levels
before or after treatment. The amount of initial DNA
damage was comparable between wt and mutant p53 cell
lines at both radiation doses. In contrast,wt p53 expressing
sarcoma cells were markedly less able to repair radiation-
induced damage compared to their mutant counterparts
after both 5 and 10 Gy irradiation.24 hr after 10 Gy irradia-
tion, only 11± 15% of GST-p gene remained intact in wt
p53 cells, compared to 50± 100% in mutant p53 cells
(p<0.05, t-test).
Conclusion: These results indicate that p53 may have
an additional important function to inhibit DNA repair in
injured cells where downstream p53 pathways of cell cycle
arrest and apoptosis are not as prominent after cellular
stress, thereby eliminating potential genomic damage from
the population and enhancing the cytotoxic effect of radia-
tion.These data support further investigation of p53 restora-
tive strategies as a means to improve the therapeutic benefit
from radiation in human sarcomas.
BONE AND SOFT TISSUE PATHOLOGY
CONSULTATION PRACTICE: A REVIEW OF
50 CASES
B. M.Wehrli,V. L. Fornasier
Vancouver General Hospital,Vancouver, BC and
Wellesley Central Hospital,Toronto, Ontario, Canada
Background: Since 1995, all new oncology patients at the
Princess Margaret Hospital (PMH), prior to their receiving
treatment, are required to have their pathology reviewed by
a designated PMH consultant pathologist. This review is
performed both to con® rm the existing diagnosis and to
ensure consistency in grading and staging of tumors.
Through an examination of this review process, we hope to
gauge the demographic scope of our consult service, to
ascertain the degree of efficiency and effectiveness of our
existing consultation protocol and to determine speci® c
areas which could be improved.
Design: A retrospective review of 50 cases, received by
the soft tissue and bone review pathologist between
February 27, 1998 and July 30, 1998, was performed. Each
case consisted of the consultant’s report, and either the
original pathology report or a letter of request for consulta-
tion, as well as any glass slides available for review. Criteria
examined included: hospitals originating consults,
turnaround time, availability of original pathology report,
the nature of material sent for consult purposes, the nature
of the gross and microscopic descriptions of specimens
from the originating hospitals, and the concordance of
initial diagnosis with the consultant diagnosis.
Results: The 50 consultation cases originated from 28
different hospitals, with all cases originating within Ontario
with the exception of 6 cases, 2 of which originated in
Quebec, and one case each in Newfoundland, New
Brunswick, Saskatchewan, and Alberta. Turnaround time
ranged from one calendar day to 104 calendar days, with
an average of 10 days. Of the 50 consultation cases, 40
(80%) were accompanied by copies of the original pathology
reports and 10 (20%) were not.The specimens described
in the dictation reports consisted of 15 resections, 20
excisional/incisional biopsies, 4 core biopsies, and one ® ne
needle aspiration biopsy. Most gross and microscopic
descriptions of the specimens received from the originating
hospitals were adequate. Fifteen (41%) of 37 cases
demonstrated diagnostic concordance, whereas 22 (59%)
of 37 cases did not demonstrate such concordance. Of
these 22 cases in which a diagnostic discrepancy was evident,
7 (32%) represented major non-concordance. In 5 of these
7 major non-concordant diagnoses, the referring diagnosis
was malignant and the consultant diagnosis was benign,
and in the remaining 2 cases, the referring diagnosis was
benign and the consultant diagnosis was malignant. The
remaining 15 (68%) of 22 non-concordant diagnoses were
minor in nature, with all demonstrating concordance
concerning the benign or malignant nature of the specimen.
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tion practice receives varying specimens from a widespread
area. The non-concordant diagnostic rate between refer-
ring pathologists and the consultant is considerable. Patients
who are diagnosed with sarcomata, should have their
pathology reviewed by a bone and soft tissue consultant
prior to radical therapy.
CT-GUIDED BRACHYTHERAPYÐ A
REVIEW OF 22 PATIENTS TREATED WITH
INTERSTITIAL IMPLANTS FOR SKELETAL
TUMORS
K. M. Lee, H. D. Suit, I. J. Spiro
Purpose: CT-guided technology can be used to enhance
precision of dose delivery in brachytherapy (BRT). This
paper is a review of 26 CT-guided BRT performed on 22
patients with tumors at skeletal sites.
Methods and materials: The records of the 22 patients
were retrospectively reviewed with regards to patient
characteristics, histological diagnosis, treatment, BRT
technique, tumor control, palliative bene® t and complica-
tions. BRT was performed either intraoperatively or percu-
taneously with the use of CT imaging for placement of
catheters.
Results: Between 1993 and 1998, 22 patients were treated
with CT-guided BRT to 26 anatomical sites, mainly
involving the axial skeleton.Histological diagnoses included
chordoma, osteosarcoma, chondrosarcoma, adenocarci-
noma and other connective tissue tumors. Nine patients
presented with primary tumor while 13 had recurrent
tumors including 11 with metastatic disease. Seven patients
had previous irradiation at the BRT sites. Of the 15 BRT
procedures performed with curative intent, there were 3
local failures including 1 with distant metastasis, 2 regional
recurrence and 3 distantrelapses.Of the 11 BRT procedures
performed with palliative intent, there were 2 local failures
also with distant metastasis, 1 regional recurrence and 4
distant relapses. The main palliative bene® t was de® nite
pain relief after 17 (71%) BRT procedures. The main
BRT-related complications were wound problems seen after
5 (19%) BRT procedures.
Conclusion: CT-guided BRT can be used in the manage-
ment of tumors at skeletal sites, in particular the axial
skeleton where a high tumor dose can be delivered with a
marked dose gradient through the spinal cord.This relatively
new technique remains under further evaluation and
undergoes constant ® ne-tuning.
THE INTERGROUP
RHABDOMYOSARCOMA STUDY GROUP
(IRSG): PROGRESS AND PROPOSALS FOR
THE NEXT STUDY, IRS-V
R. B. Raney, J. R.Anderson,W. Crist,
H. M. Maurer
IRSG of the Children’s Cancer Group and Pediatric
Oncology Group, UT MD Anderson Cancer Center,
Houston,TX 77030, USA
In 1972, members of the pediatric oncology cooperative
groups formed the IRSG with support from the National
Cancer Institute to study rhabdomyosarcoma (RMS) and
undifferentiated sarcoma (UDS) in previously untreated
patients less than 21 years of age. Since then, 3 successive
protocols have shown improved overall 5-year survival rates,
from 55%, in IRS-I to 71% in IRS-III (P<0.001; J Clin
Oncol 1995;13:610). IRS-IV (1991± 1997) tested a rand-
omized comparison of vincristine, actinomycin D, and
cyclophosphamide (VAC, with C=2.2 gm/m2/course) vs.
VAI (ifosfamide, 9 gm/m2/course) vs. VIE (etoposide,
500 mg/m2/course) for patients with localized disease.
Conventional radiotherapy (XRT; 50.4 Gray) was compared
to hyperfractionated XRT (59.4 Gray) for patients with
localized, gross residual sarcoma. Preliminary results should
be available in 11/98. Proposals for IRS-V therapy are based
on stratifying patients into 4 categories according to the
probability of failure: low-risk, intermediate-risk with
embryonal (EMB) RMS, intermediate-risk with alveolar
(ALV) RMS or UDS, and high-risk patients with metas-
tases (Stage 4) at diagnosis. Tumor specimens will be
subjected to cytogenetic and molecular analyses, in order
to ascertain whether prognostic subgroups can be identi-
® ed among the patients with EMB and ALV RMS and
UDS. The general strategy is to design therapy based on
the likelihood of cure.The Table shows the four categories
of patients, the 3-year failure-free survival (FFS) and overall
survival estimates, and the types of treatment to be
administered.
Category %
3-year
FFS
%
3-year
Survival
Treatment
Low-risk 88 95 VA ± CPM ± XRT
Intermediate EMB,
including Stage 4
<10 yr.
45± 76 51± 84 VAC with › CPM +
XRT
Intermediate
ALV/UDS
51± 72 61± 81 VAC + Topotecan +
XRT
High-risk EMB >10
yr. + ALV/UDS
22 38 New-agent window,
then VAC + XRT
Supported in part by Grants CA-24507 and CA-30138
from the National Cancer Institute.
DESMOID TUMOR: OUTCOME AND
PROGNOSTIC FACTORS FOLLOWING
SURGERY, RADIATION, OR COMBINED
SURGERY AND RADIATION
M. T. Ballo, G. K. Zagars, A. Pollack,
P. W. T. Pisters, R. A. Pollack
The University of Texas M.D.Anderson Cancer Center,
Houston,Texas 77030, USA
Purpose:To evaluate the therapeutic value of resection alone,
radiation alone or combined modality therapy for desmoid
tumors.
Patients and methods: One hundred and eighty-® ve
consecutive patients with desmoid tumors treated at our
institution between the years 1965 and 1994 were
retrospectively reviewed and form the cohort of this analysis.
Surgery alone was the treatment for 122 patients, surgery
and radiation for 46 (combined modality), and radiation
alone for 21.There were 108 women and 81 men. Patients’
ages ranged from 1± 81 years, with a mean and median of
31 and 29 years, respectively. Size ranged from 1± 28 cm,
with a median of 8.4 and 7 cm, respectively. One hundred
and four patients (55%) presented after one (54 patients)
or more (50 patients) local recurrences. Margin status for
the surgery alone group was microscopic-positive in 40
(33%), microscopic-negative in 78 (64%), and gross-
positive in 4 (3%). Margin status for the combined modality
group was microscopic-positive in 33 (72%) and
54 Abstractsmicroscopic-negative in 13 (23%). All patients in the radia-
tion alone group were treated for gross disease. Median
follow-up was 9.4 years.
Results: The 5- and 10-year overall actuarial relapse rate
was 30% and 33%, respectively. Uncorrected survival rates
were 96%, 92%, and 87% at 5, 10, and 15 years,respectively.
For the patients treated with surgery alone the actuarial
recurrence rate was 38% at 10 years. The 10 year recur-
rence rates for the margin-negative and margin-positive
patients were 27% and 54% (p=0.003), respectively. For
the combined modality patients the 10-year actuarial recur-
rence rate was 25%. Among 13 margin-negative patients
the 10 year recurrence rate was 15%, whereas 33 margin-
positive patients had a 10 year recurrence rate of 31%
(p=0.5). The difference in recurrence rates for patients
with microscopically positive margins treated with surgery
alone versus combined modality was signi® cant (p=0.007).
On multivariate analysis only age >30 and combined
modality treatment (versus surgery alone) independently
correlated with a decreaed rate of recurrence. For patients
treated with radiation alone the 10-year recurrence rate
was 24%.
Conclusion: Wide local excision with negative pathologic
margins is the treatment of choice for most desmoid tumors.
Function sparing resection is appropriate since adjuvant
radiation abrogates the adverse impact of positive margins.
Unresectable disease should be treated with de® nitive radia-
tion with the expectation of excellent disease-free survival.
PRE-OPERATIVE CHEMOTHERAPY AND
RADIOTHERAPY (RT) FOR POOR
PROGNOSIS EXTREMITY SOFT TISSUE
SARCOMAS
B. Brockstein,T. Peabody, B. Samuels,
A. Mundt,A.Awan, M. Simon
The University of Chicaco, Chicago, IL 60637, USA
Although the majority of soft tissue sarcomas can be treated
with limb salvage surgery, a minority of tumors are unre-
sectable and require amputation or resection with a high
risk of local recurrence. For this group of patients (pts),
pre-surgical therapy with chemotherapy and radiotherapy
may allow limb salvage. Additionally, early treatment of
micrometastases may reduce the risk of distant failure and
subsequent death.We utilized the regimen of Eilber et al.
(Proc ASCO, 1994, abstract 1645) to con® rm its efficacy,
but limited its use to unresectable and marginally resect-
able pts. From 8/94 until 7/98, a total of 17 pts received 3
cycles of pre-operative chemotherapy, which was repeated,
on a case by case basis, approximately 4 weeks post-
operatively. RT (350 cGy 3 8 fractions in 10 days) was
given with (5 pts), before (2 pts), or after (7 pts) the second
cycle of chemotherapy.3 pts received no RT. Chemotherapy
consisted of: cycles 1,2,4,5Ð Ifosfamide 2800 mg/m
2/day
by 1± 2 hour (h) infusion 3 5 days; cycle 3,6 doxorubicin
60 mg/m
2 by 48 h infusion and cisplatin 120 mg/m
2 by 4 h
infusion. Demographics included; 9 males (53%) and 8
females (47%); median ageÐ 52 (21± 77); lower
extremityÐ 12 (70%), upper extremityÐ 5 (30%); metastatic
diseaseÐ 2pts (12%), localized diseaseÐ 15 (88%). Resecta-
bility included 7/13 (54%) unresectable, 4/13 (31%)
marginally resectableÐ 2/13 (15%) resectable. Number of
cycles of chemotherapy received (13 currently evaluable);
2Ð 2 pts, 3Ð 3 pts, 4Ð 3 pts, 5Ð 3 pts, ‡ 6Ð 2 pts. 14 pts
received full RT dose and 3 additionally received a
postoperative boost. 3 pts received no RT (2Ð progression
of metastases, 1Ð amputation due to rapid progression).
Major complications of preoperative therapy (13 evaluable
currently) included ifosfamide neurocortical toxicityÐ 5 pts,
proximal renal tubular acidosisÐ 1 pt, hemorrhagic
cystitisÐ 1 pt.Wound healing was delayed in 3/13 pts (23%).
Radiologic responses were PRÐ 2, stableÐ 4,
progressionÐ 3, unevaluable 8. Histological responses were
(12 currently evaluable) ‡ 90 necrosisÐ 6/11 (55%), 50± 89%
necrosisÐ 2/11 (22%), <50% necrosisÐ 3/11 (33%), 1Ð no
surgery.With a median follow-up of 12 months, there has
been 1/13 local recurrence, 2/13 new distant failures, 2/13
with progression of metastatic disease, and 1/13 second
primary. 2/13 (15%) pts have died, and 2/13 (15%) have
required amputation. Of particular interest, all 3 synovial
sarcomas were non-responders. We conclude that in this
group of patients with unresectable or difficult to resect
disease, aggressive preoperative chemotherapy and RT
allowed limb salvage in most patients (85%). We plan to
modify the protocol to include additional doxorubicin
pre-operatively and post-operatively.
IMMUNOTHERAPY OF METASTATIC
LEIOMYOSARCOMA WITH AUTOLOGOUS
TUMOR VACCINE-PRIMED LYMPH NODE
LYMPHOCYTES AND INTERLEUKIN-2
V. K. Sondak, G. Jiang, R. I. Cross, L. H. Baker,
J. J. Mule Â ,A. E. Chang
Multidisciplinary Sarcoma Clinic, University of
Michigan Comprehensive Cancer Center, Ann Arbor,
MI 48109, USA
Metastatic leiomyosarcoma, whether it emanates from the
gastrointestinal tract, the uterus or other soft tissue or
visceral sites, has proven difficult to treat with conventional
modalities. New approaches are clearly worth evaluating.
Several disparate lines of reasoning support investigations
of immunotherapy in this disease: Some forms of leiomy-
osarcoma are more frequent in immunosuppressed patients
and may be associated with Epstein-Barr virus, providing a
potential antigenic target. HumanT cells are now known to
be capable of recognizing antigens on human sarcoma cells.
Some patients with metastatic leiomyosarcoma have
relatively protracted courses and slowly progressive disease.
From May 1997 through July 1998, we entered 8 patientsÐ
ages 29 to 70Ð with metastatic leiomyosarcoma onto an
adoptive immunotherapy protocol involving vaccination
with irradiated autologous tumor cells plus BCG followed
10 to 14 days later by removal of the regional lymph nodes
draining the vaccine sites. These ª vaccine-primedº lymph
node lymphocytes were sequentially cultured in vitro in
anti-CD3 monoclonal antibody (OKT 3) and a low
concentration of interleukin 2 (60 Cetus U/ml) for 2 to 3
weeks. Unless tumor progression supervened, activated
lymphocytes were administered intravenously followed by
moderate-dose interleukin 2 (180,000 Cetus U/kg t.i.d. for
15 doses). Patients manifesting stable or regressing disease
were retreated with a second course of interleukin 2.To be
eligible, patients had to have accessible or previously cryo-
preserved tumor and a life expectancy of at least 3 months.
Of the 8 patients, the primary site was gastric in 2,
uterine in 2, and small bowel, renal, retroperitoneal and
soft tissue in 1 each.All patients had measurable metastatic
disease in liver (6 patients) or lung (2 patients) as well as
soft tissue sites;no patient had exclusively soft tissue disease.
Four patients (1 uterine, 3 gastrointestinal primaries) had
received no prior chemotherapy, the remaining patients
had all received doxorubicin alone or with ifosfamide.Two
patients had rapid progression of tumor and were removed
from study prior to the administration of interleukin 2. The
Abstracts 55remaining 6 patients were all treated with activated
lymphocytes plus interleukin 2 and tolerated the therapy
well. Dose reductions were required in 2 cases because of
renal or hepatic toxicity, no patients required ICU admis-
sion or vasopressors. Of the ® ve patients who have been
assessed after their initial course of therapy, four met the
study conditions for and received a second course of inter-
leukin 2.
Adoptive immunotherapy with autologous tumor vaccine-
primed lymph node lymphocytes and interleukin 2 is
complex and resource-intensive, but feasible in patients
with metastatic leiomyosarcoma. Further investigations of
this and other forms of immunotherapy appear to be
warranted in this disease.
Acknowledgements: Funded by NIH grants
1R21CA72034 and M01-RR00042.
IMMUNOGENICITY OF CHROMOSOMAL
FUSION PROTEIN SEQUENCES
ASSOCIATED WITH SYNOVIAL SARCOMA
B. S.Worley,T. J. Goletz, L. J. Helman,
J. A. Berzofsky
Metabolism Branch and Pediatrics Branch, National
Cancer Institute, National Institutes of Health,
Bethesda, MD 20892, USA
Synovial sarcoma (SS) is an aggressive, soft-tissue
malignancy occurring primarily in the extremities of
adolescents and young adults. More than 70% of SS cases
have been attributed to a t(X;18)(p11;q11) chromosomal
translocation which fuses the SYT gene from chromosome
18 to either the SSX1 or SSX2 gene on chromosome X.
The resulting SYT-SSX1 and SYT-SSX2 fusion proteins
are believed to function as aberrant transcriptional regula-
tors.The fusion of SYT to SSX1 or SSX2 creates a unique
peptide sequence at the breakpoint which is not expressed
in normal cells. Because the t(X;18)(p11;q11) transloca-
tion is associated with SS tumor cells, we proposed that the
SYT/SSX fusion protein could serve as a tumor-associated
antigen.To determine the immunogenicity of the breakpoint
peptide sequence, two representative overlapping 17mer
peptides (SS1 and SS2, both present in the two types of
fusions)were synthesized,both of which span the breakpoint
region. Immunization of C57BL/6 mice with SS1-pulsed
spleen cells elicited an SS1-speci® c, CD8
+, class I-restricted
T cell response, as seen by in vitro CTL, activity analysis.
Efforts are ongoing to develop an animal model in which to
assess the in vivo efficacy of the peptides for anti-tumor
therapies. Application of this approach in novel immuno-
therapies depends upon the binding of these peptides to
HLA molecules. Therefore, to assess binding of SS1 and
SS2 to various HLA molecules, these peptides were tested
using T2 cells transfected with HLA molecules and FACS
analysis.The SS2 peptide speci® cally bound both HLA-B7
and HLA-B27 at 100 m M concentration, increasing expres-
sion of the class I HLA molecules about 2-fold. The SS1
peptide also speci® cally bound HLA-B7 at 100 m M
concentration, increasing HLA-B7 expression about
3.5-fold. These results suggest that the SYT-SSX1 and
SYT-SSX2 fusion proteins potentially encode an antigenic
amino acid sequence which speci® cally binds human HLA
molecules.This may be useful in the development of novel
immunotherapies for SS.
PRELIMINARY RESULTS OF A TWO-ARM
PHASE 2 TRIAL OF GEMCITABINE IN
PATIENTS WITH GASTROINTESTINAL
LEIOMYOSARCOMAS AND OTHER
SOFT-TISSUE SARCOMAS (STS)
S. R. Patel, J. Jenkins, N. E. Papadopoulos,
M. A. Burgess, C. Plager, P. W. T Pisters,
B. W. Feig, K. Hunt, A. Pollack, G. Zagars,
R. E. Pollock, R. S. Benjamin
The Sarcoma Center, University of Texas M.D.
Anderson Cancer Center, 1515 Holcombe Blvd.,
Houston,Texas 77030, USA
A limited number of chemotherapeutic agents have activity
in soft-tissue sarcomas. It is therefore important to test
newer agents for their activity in this disease. We are
currently evaluating Gemcitabine, a nucleoside analog with
activity in a variety of solid tumors, in a two-arm phase 2
study.Patients with recurrent/metastatic soft-tissue sarcomas
who have received or refused standard chemotherapy with
adriamycin and ifosfamide constitute one arm and patients
with GI leiomyosarcoma irrespective of prior chemotherapy
exposure (due to their know resistance to standard
chemotherapy) constitute the other arm. Gemcitabine was
given at a dose of 1000 mg/m
2/wk 3 7 followed by 1 week
off and re-staging to assess response. Patients with
responding or stable disease were then continued at a dose
of 1000 mg/m
2/wk 3 3 followed by 1 week off, and cycles
were repeated every 4 weeks until maximum response or
progression.A total of 19 patients are evaluable for response,
11 GI leiomyosarcomas and 8 other STS.There were eight
males and 11 females and the median age was 53 (28± 75)
years. All patients had a PS for 0± 1. One patient out of 11
GI leio patients has demonstrated a minor response, while
two patients out of the 8 other STS have achieved partial
responses. One of the responders had a metastatic angiosa-
rcoma to lungs and the other one had lung metastases from
a leiomyosarcoma of uterine origin. Treatment was gener-
ally very well tolerated. Four patients experienced grade 3
neutropenia and three patients experienced grade 3 throm-
bocytopenia leading to delays in therapy without any other
consequences. Two patients had a grade 3 increase in
transaminase levels which was self-limiting. Two patients
had grade 3 myalgias.This preliminary data is encouraging
and suggestive of activity of Gemcitabine in soft-tissue
sarcomas. Our study is continuing to accrue more patients
to better de® ne the level of activity.
A PHASE II STUDY OF RALTITREXED
(`TOMUDEX’) AS SECOND OR THIRD LINE
TREATMENT FOR PATIENTS (PTS) WITH
ADVANCED SOFT TISSUE SARCOMAS
(ASTS) REFRACTORY TO DOXORUBICIN
CONTAINING REGIMENS
J.-Y. Blay, I. Judson, S. Rodenhuis, C. Hermans,
M. Smith*, M. van Glabbeke, J.Verweij
The EORTC SoftTissue and Bone Sarcoma Group
(STBSG), EORTC, 1200 Brussels, Belgium; *Zeneca
Ltd, UK
ASTS refractory to doxorubicin (dox) and ifosfamide (ifo)
are highly resistant to chemotherapy. The investigation of
new drugs is therefore warranted in these pts.To establish
56 Abstractsthe efficacy and safety of Raltitrexed (`Tomudex’) in ASTS
refractory to one or two lines of dox and ifo containing
regimens, a phase II study was conducted between August
1997 and December 1997 in 8 centers of the EORTC
STBSG group. Raltitrexed was given at 3 mg/m2/course as
a 15 min IV infusion every 3 weeks. 23 pts were included
and 21 are evaluable for toxicity and response. Median age
was 54 (range 25± 73) with 15 males and 6 females.Perform-
ance status was 0 in 9 (43%) pts, 1 in 12 (57%) pts. 16 pts
had previously received chemotherapy in metastatic phase,
4 as adjuvant, and 1 both.The primary tumor was located
in the trunk (n=11), in the limbs (n=7), in the head and
neck (n=3). The predominant histology was leiomyosar-
coma (n=7, 33%). Respectively 4, 13, 1, 1,and 2 pts received
1, 2, 4, 5, or 6 courses of Raltitrexed.The best response was
stable disease in 4 (19%) pts, and disease progression in 17
pts (81%), with a median time to disease progression of 6
weeks. The treatment was well tolerated with only 1 pt
experiencing grade 4 neutropenia and thrombopenia (5%),
1 grade 3 nausea (5%), 1 (5%) lethargy, 1(5%) headache,
1 (5%) asthenia. A single pt (5%) experienced febrile
neutropenia.We conclude that Raltitrexed is an ineffective
treatment for ASTS failing conventional chemotherapy with
dox and ifo.Tomudex is a trademark, a property of Zeneca
Ltd.
FIVE-YEAR SURVIVORS IN PATIENTS
(PTS) WITH ADVANCED SOFT TISSUE
SARCOMA (ASTS) TREATED WITH
DOXORUBICIN: A STUDY ON 1742
PATIENTS (STBSG)
J.-Y. Blay, M. van Glabbeke, O. S. Nielsen,
A. T. van Oosterom,T.Tursz, J. W. Oosterhuis,
J.Verweij
The EORTC Soft Tissue and Bone Sarcoma Group
(STBSG), EORTC, 1200 Brussels, Belgium
The characteristics of pts with ASTS still alive 5 years (yrs)
after initial treatment with doxorubicin (DXR), i.e. long
term survivors (LTS), were analyzed among the 1742 pts
treated between 1976 and 1990 in trials of EORTC STBSG
group. The median overall survival of this series was 11.3
months and the projected 5-years (yrs) survival was 8.6%.
39 pts were alive at 5 yrs among the 1308 uncensored pts.
The percentages of females (69% vs 49%), of grade 1
tumors (30% vs 6%), and of pts with an initial perform-
ance status (PS) of 0 (49% vs 27%) were superior in the
LTS subgroup as compared to other pts (p<0.01).
Histological subtypes were not signi® cantly different in
LTS as compared to other pts. LTS pts less frequently had
grade 3 tumors (35% vs 64%), and liver metastasis (5% vs
18%) (p<0.01). Despite of these differences, LTS were
observed in all categories of pts.A complete response (CR)
to DXR was a major parameter correlated to 5-yrs survival:
respectively, 18% (11/60) of pts in CR, 4% (9/215) of pts
in partial response (PR), 2% (13/482) of pts in stable
disease (SD), and 1% (3/372) of pts in progressive disease
(PD) after DXR were alive at 5 yrs. Patients in CR, PR, SD
and PD represented 31%, 25%, 26%, and 8% of LTS
respectively.In multivariate analysisindependent parameters
correlated to CR and 5-yrs survival were similar to those
correlated to overall survival in the same series, i.e. age,
liver metastases, PS, grade I tumors. In conclusion, LTS
are observed in all prognostic subgroups of pts with ASTS
treated with DXR, in particular among pts in CR, in whom
5-yrs survival is 18%. Achievement of CR should be the
primary aim of chemotherapy. This work was supported by
the Prix Pierre Bardoux.
A NEW PROGNOSTICATION SYSTEM FOR
ADULT SOFT TISSUE SARCOMA OF
EXTREMITY AND TRUNK WALL, BASED
ON TUMOR SIZE,VASCULAR INVASION,
AND MICROSCOPIC TUMOR NECROSIS
(THE SIN-SYSTEM)
P. Gustafson, M.A Ê kerman,T. A.Alvega Ê rd,
J. M. Coindre, C. D. M. Fletcher, A. Rydholm,
H.Wille Â n
University Hospital, Lund, Sweden, Institut Bergonie Â ,
Bordeaux, France; Brigham andWomen’s Hospital,
Boston, MA, USA
A clinically useful prognostication system should be
reproducible and give good separation between two
groupsÐ one with good and one with poor prognosis. We
have recently proposed a system based on three negative
prognostic factors large tumor size, vascular invasion, and
microscopic tumor necrosis. Tumors which exhibit 2 or 3
factors are categorized as high-grade, the others as
low-grade. We have now tested this system for reproduc-
ibility both as regards classi® cation of necrosis and vascular
invasion, and as regards prognostic strength related to
grading.
We selected 200 adult patients with STS of the extremity
or trunk wall, 100 from the MusculoskeletalTumor Center,
Lund Sweden and 100 from the Institut Bergonie Â ,
Bordeaux, France.All patients had been treated by surgery.
The median follow-up for the 117 survivors was 10 (1.5± 27)
years. All slides from all tumors were reviewed independ-
ently by three groups of pathologists for the presence or
absence of vascular invasion and microscopic tumor
necrosis, without knowledge of the clinical course. Tumor
size was considered same. The prognostic strength was
compared using the grading obtained by the different
pathologists.Concordance in classi® cation was assessed by
Kappa-analysis. Outcome related to grading was assessed
by Kaplan-Meier technique. Concordance in classi® cation
of vascular invasion, microscopic tumor necrosis, and
grading was seen respectively in 156 (78%), 154 (77%),
and 167 (84%) of the 200 tumors. Based on the different
observers grading, the cumulative 5-year metastasis-free
survival rate in the 200 patients varied for patients with
low-grade tumors between 0.85 and 0.80 and for patients
with high-grade tumors between 0.48 and 0.43.The kappa-
value for grading between all three groups was 0.77.
Classi® cation of vascular invasion and microscopic tumor
necrosis seems to have acceptable reproducibility.This so
called SIN-system gave similar survival rates when used by
different observers and applied to different series of STS
patients. It gave good separation between patients into two
groups with high or low risk for metastasis.
CAN WE EXPLAIN THE DIFFERENT
PROGNOSTIC FACTORS FOR RESPONSE
AND SURVIVAL IN THE VARIOUS
HISTOLOGICAL SUBTYPES OF
ADVANCED SOFT TISSUE SARCOMA? AN
ANALYSIS OF 2185 PATIENTS FROM THE
EORTC SOFT TISSUE AND BONE
SARCOMA GROUP DATABASE
M. van Glabbeke, J. W. Oosterhuis,A. T. van
Oosterom, O. S. Nielsen,A. Le Cesne,
J. Radford, H. Mouridsen, S. Rodenhuis,
A. Kirkpatrick, J.Werweij
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STBSG
This prognostic factors analysis included 2185 patients
with advanced soft tissue sarcomas, treated in 7 clinical
trials investigating anthracycline containing regimens as
1st line chemotherapy. Overall survival (median: 51 weeks)
and response to chemotherapy (26% CR/PR) were the two
end-points. Cofactors were sex, age, performance status,
prior therapies, presence of locoregional or recurrent
disease, lung, liver, and bone metastases at trial entry, delay
since initial sarcoma diagnostic, histological type and grade.
Both univariate and multivariate analyses were performed.
Multivariate analysis of survival (Cox model) selected
the following variables as favorable prognostic factors: good
performance status (P<0.0001), absence of liver metas-
tases (P=0.0001), low histological grade (P=0.0002), long
delay since initial diagnostic (P=0.0004) and young age
(P=0.0045). Multivariate analysis of response (logistic
model) selected the following variables as favorable
prognostic factors: absence of liver metastases (P<0.0001),
young age (P=0.0024), high histological grade (P=0.0051)
and liposarcoma (P=0.0065).
The univariate analysis also underlined the prognostic
importance of histological subtype. Patients with liposar-
coma and synovialsarcoma had a signi® cantly better survival
than patients with other cell types, patients with malignant
® brous histiocytoma had a worse survival; liposarcoma
patients had a higher response rate and leiomyosarcoma
patients had a lower response rate.
Our study con® rms that high grade tumors are chemo-
sensitive, despite their poor survival prognosis. As far as
histological subtype is concerned, liposarcoma appeared as
chemosensitive tumors with a good survival prognosis.
These tumors are usually low grade, which explains the
favorable survival, but not the observed high response rate.
Other histological subtypes dropped out of the multi-
variate models, but the present analysis explained their
prognostic value on the basis of their correlation with other
prognostic factors.
We concluded that, for advanced soft tissue sarcoma,
response to chemotherapy is not predicted by the same
factors as overall survival. This suggests that response
should not be the only end-point for evaluation of new
agents. Our future plans include the addition of original
anatomic site of disease in the model.We are expecting to
better characterize the characteristics and prognostic of
the different histological subtypes, and will evaluate if
phase II trials of new agents should address speci® c
subtypes.
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Introduction: Malignant peripheral nerve sheath tumors
(MPNSTs) are a relatively rare type of soft tissue sarcoma.
Half of the patients suffer from von Recklinghausen’s
neuro® bromatosis (NF-1). Cytogenetic studies in small
groups of patients revealed complex karyotypes with no
consistent changes. A computer assisted cytogenetic
analysis was used to determine recurrent cytogenetic
alterations in MPNSTs and to allow direct cytogenetic
comparison between NF-1 associated and sporadic
MPNSTs.
Material and methods: Karyotypes of 53 MPNSTs (46
from the literature and 7 new cases) were interpreted and
the gains and losses of chromosomal material in 86 ISCN-
described chromosomal regions as well as the breakpoints
were entered into a database.To detect signi® cant gains or
losses of chromosomal material, 95%-con® dence intervals
were constructed. Differences between NF-1 associated
and sporadic MPNSTs were studied by the creation of
karyographs and statistical analysis.
Results: Signi® cant (p<0.05) loss was observed in 9p2,
11p1, 11q2 and 18p1. Gain of chromosomal material
was found in chromosome 7, especially 7q1 (p<0.05).
Most involved breakpoints were: 1p13, 1q21, 7p22, 9p11,
17p11, 17q11, 22q11. Differences between NF-1 associ-
ated and sporadic MPNSTs included a relative loss of
chromosomal material in NF-1 associated MPNSTs in
1p3, 4p1 and 21p1-q2 as well as a relative gain in 15p1-q1.
Differences in breakpoints were observed in 1p21-22
(28% of NF-1 vs 0% of sporadic MPNSTs), 1p32-34
(17% vs 0%), 8p11± 12 (7% vs 27%) and 17q10± 12
(24% vs 7%).
Conclusion:This computer assisted approach shows that
losses in 9p2 and gains in 7q1 could be of oncogenetic
importance in MPNSTs. Loss of 17q1, on which the
NF-1 gene has been located (17q11.2), is not a common
cytogenetic ® nding in NF-1 associated MPNSTs. The
observed differences between NF-1 associated and
sporadic MPNSTs might re¯ ect different oncogenetic
pathways.
P-GLYCOPROTEIN AS A PREDICTOR OF
OUTCOME IN OSTEOSARCOMA
F. J. Hornicek, M. C. Gebhardt, M. W. Wolfe,
F. D. Kharrazi, H.Takeshita, H. J. Mankin
Orthopaedic Oncology Unit, Massachusetts General
Hospital and Children’s Hospital, Harvard Medical
School, Boston, MA 02114, USA
Purpose:To establish a relationship between the expression
of P-glycoprotein by osteosarcomas and the rate of
metastasis and death.
Materials and methods: A retrospective review of 172 oste-
osarcoma patients diagnosed between 1987 and 1992 was
performed. Forty patients had p-glycoprotein levels avail-
able. The majority of the osteosarcomas were stage II-B
(33 patients), with the remaining seven being stage III.
Tumor sites included 25 femora, 7 humeri, 5 tibiae, and
one each of pelvis, radius and ® bula. The expression of
P-glycoprotein by cultured tumor cells from biopsy
specimens was determined using immuno¯ uorescent micro-
scopy.
Results: More patients with detectable P-glycoprotein
(12/18 or 67%) developed metastases as compared to those
patients with undetectable P-glycoprotein (9/22 or 41%;
N.S.). Similarly, ten of 18 patients (56%) with tumors
expressing P-glycoprotein died of disease, while only 4 of
22 (18%) with no detectable P-glycoprotein died (chi-
square; p<0.02). Among the patients with stage III disease
58 Abstractsat presentation, two of three with P-glycoprotein expres-
sion died, while only one of four without P-glycoprotein
died.
Conclusion: Expression of P-glycoprotein by tumor cells
appears to be associated with an increased incidence of
death in stage II and III osteosarcoma.
EVALUATION OF EWING’S SARCOMA
INFORMATION ON THE INTERNET
G. J. Golladay, J. S. Biermann, M. L. Green® eld,
L. H. Baker
University of Michigan Comprehensive Cancer Center,
Ann Arbor, MI 48109, USA
Background: The Internet is a rapidly expanding and
widely used information source. Although many people
are using the Internet to search for medical information,
there are no guarantees that information retrieved is
pertinent or correct.We chose Ewing’s sarcoma as a search
item to evaluate the accuracy and relevance of Internet
medical search results.
Methods: We developed a guide to evaluate all medical
information that might appear on Web pages, but limited
our study to a search of Ewing’s Sarcoma. The guide
demonstrated good interobserver and intraobserver reli-
ability during preliminary and ® nal study testing. We
evaluated the ® rst 100 URLs retrieved using four search
engines searching the phrase, ª Ewing’s Sarcomaº . We
evaluated each Web page for type of medical information
presented, references, the presence of peer review, and
accuracy.
Results: Of 400 search-engine generated URLs, there
were 29 duplications. Only 170 Web pages contained
medical information relevant to our search term. 34.5% of
Web pages contained no reference to peer review. Six percent
of non-peer reviewed Web pages contained factually incor-
rect information.
Conclusions:We developed a reliable rating instrument to
evaluate medical information on the Internet for relevance
to the search term, type of medical information presented,
and presence of peer review. We demonstrated that
searching for medical information regarding Ewing’s
sarcoma in the Internet yielded both peer reviewed and
non-peer reviewed information and found that factual
inaccuracies in the non-peer reviewed material were
present, at a rate of six percent. Although this number is
relatively small, some of the inaccuracies identi® ed had
signi® cant potential to lead to serious harm to patients
with Ewing’s sarcoma.
PATIENT USE OF THE INTERNET FOR
MEDICAL INFORMATION IN AN
OUTPATIENT CANCER CENTER
G. J. Golladay, M. L. Green® eld, L. H. Baker,
J. S. Biermann
University of Michigan Comprehensive Cancer Center,
Ann Arbor, MI 48109, USA
Background: While the Internet is a growing source of
medical information for patients as well as health care
providers the extent to which patients are using the
Internet to gain information related to their diagnosis or
treatment or both remains obscure. To assess patient use
we studied a sample of comprehensive cancer center
patients after designing and ® eld testing a speci® c
questionnaire.
Methods: All patients presenting to the outpatient clinics
of two faculty (JSB and LHB) during a three week period
were administered a con® dential questionnaire. The
questionnaire was designed to measure the use of the
Internet, the search method by which information was
retrieved, who obtained the information, and the attitude
of the patient towards the new information obtained.
Patients were also asked to respond to the same question-
naire by mail at a later date in order to assess the reliability
of the instrument.
Results: 200 patients participated. 87 of the surveyed
patients (43.5%) used the Internet to search for medical
information. 43 patients used the Internet themselves while
78 someone else to search the Internet for them (including
34 of the primary users). 37 of the users would recom-
mend the Internet as an information resource for other
patients becuse of the speed and ease of information
retrieval the Internet offers. 10 patients expressed concern
about the large volume and credibility of information acces-
sible on the Internet. Sufficient patients volunteered to
repeat the use of the questionnaire to assure adequate reli-
ability.
Conclusions: Nearly half of surveyed patients in this sample
had obtained Internet information related to their
diagnosis, prognosis,or treatment.The Internet is a rapidly
developing medical information resource for patients that
requires physician input for optimal patient bene® t. To
this end, our Cancer Center has a patient education
resource center that assists in teaching patients and
families how to do searches and we maintain a committee
of health care providers who recommend Web sites that
are deemed accurate and useful.
THALLIUM UPTAKE IN CHONDROID
LESIONS
K. T.Templeton,T. G. Raveill, O.Taw® k
University of Kansas Medical Center, Kansas City,
Kansas 66160, USA
Heterogeneity within cartilagenous lesions can make grading
and surgical planning difficult.In conjunction with standard
imaging modalities,
201Thallium has been utilized in the
evaluation of bone and soft tissue sarcomas, with 100
percent uptake noted in primary and recurrent sarcomas.
It has also been shown to have an accuracy rate of 97
percent in determining benign vs. malignant bone and soft
tissue lesions, with high-grade sarcomas occasionally
demonstrating a ª doughnutº sign. In chondroid lesions,
T1201 has been shown to differentiate intermediate/high
from low-grade/benign lesions.
T1201 imaging was utilized in three patients with
radiographic evidence of chondroid lesions which were read
as consistent with low-grade chondrosarcoma on open
biopsy.T1201 scans were obtained to evaluate for the pres-
ence and location of higher grade areas within the lesions.
All patients received 5mCi ofT1201 with early (20 minute)
and, in two, delayed (3 hour) imaging. Both lesions were
also scanned with SPECT. After resection, histological
mapping of the tumors was performed to compare with
T1201 images.
The areas noted on histological exam to be low-to-
intermediate grade demonstrated a T1201 uptake ratio
(compared to the contra lateral normal site) of 0.99 to
1.11. This was unchanged on delayed images (ratios 1.06±
Abstracts 591.12). In comparison, the higher grade areas had uptake of
1.26± 1.64 cts/pixel (or 1.38± 1.47 max cts) of the contra
lateral normal site. In addition, four other patients with
chondroid lesions, diagnosed radiographically, have been
followed with periodic clinical exam and roentgenograms.
All had T1201 scans with uptake noted to be equivalent to
the contra lateral site. All of these patients remain
asymptomatic with no change in their radiographs during
follow-up (range 5 mos.± 4 yrs.)
T1201 uptake, mediated through the Na-K ATPase
dependent pump, is dependent not only on blood ¯ ow but
also tumor of cell viability and activity. With a degree of
heterogeneity seen in chondroid lesions, T1201 may help
illucidate those tumors, and regions within tumors, that are
more aggressive and therefore need more aggressive
management despite a relatively low grade as seen on open
biopsy.
CHEMOTHERAPY, IRRADIATION, AND
SURGERY FOR FUNCTION-PRESERVING
CURATIVE THERAPY OF PRIMARY
EXTREMITY SOFT TISSUE SARCOMAS:
INITIAL TREATMENT WITH I-MAP +
GM-CSFÐ PRELIMINARY REPORT
J. H. Edmonson, I. A. Petersen,T. C. Shives,
M. G. Rock, M. G. Haddock, F. H. Sim,
W. J. Maples, M. I. O’Connor, L. L. Gunderson,
M. L. Foo, D. J. Pritchard, J. C. Buckner,
S. L. Stafford, M. R. Mahoney
Mayo Clinic, Rochester, MN 55905, USA
Between 3/94 and 10/97 20 women and 19 men, median
age 51 yrs (27± 76 yrs), were treated for cure of their high
grade primary extremity and limb girdle soft tissue sarcomas
with preoperative chemotherapy and irradiation. This
involved two monthly cycles of IMAP (ifosfamide
2,500 mg/m
2 + MESNA 2,500 mg/m
2 daily for two days
with mitomycin 4 /mg/m
2, doxorubicin 40 mg/m
2, and
cisplatin 60 mg/m
2 added on the second day). Beginning
six days before chemotherapy each month they received
four days of GM-CSF (sargramostim) 250 mcg/m
2 S.C.
every 12 hours.This was then continued for 14 more days
the day after chemotherapy was ® nished each month.
External beam irradiation was begun at month three and
continued ® ve days weekly for approximately 4,500±
5,000 cGy in ® ve weeks, accompanied by adjuvant doses of
mitomycin 6 mg/m
2, doxorubicin 30 mg/m
2, and cisplatin
45 mg/m
2 given thrice (before, midway, and after irradia-
tion.) De® nitive surgery accompanied by intraoperative
electron irradiation or brachytherapy and/or further external
beam treatment (to a total dose of 5,500± 7,000 cGy) was
scheduled to occur after a one month rest interval. No
postoperative chemotherapy was given. Sites of origin were
thigh 23, pelvic girdle 5, leg 4, arm 3, shoulder girdle 2, and
forearm 2. Maximal tumor diameters ranged from 1.6 to
30 cm (median 10 cm). Histologic types were malignant
® brous histiocytoma 20, synovial sarcoma 5, extraosseous
osteosarcoma 4, malignant peripheral nerve sheath tumor
3, spindle cell 2, ® brosarcoma 2, and leiomyosarcoma 3.
Surgery involved radical excision in two patients,wide exci-
sion in 22 patients (1 contaminated), marginal excision in
14 (1 contaminated),and no surgical excision in one patient
(who developed brain metastasis during preoperative treat-
ment). Signi® cant complications included tissue necrosis
requiring debridement and secondary closure (1), intral-
esional hemorrhage and necrosis requiring amputation (1),
and pathologic fractures with infection requiring amputa-
tion (1). Limbs remained intact in 37 of the 39 patients.
The prescribed irradiation was received in 36 cases at Mayo
Clinic; two patients received preoperative irradiation
elsewhere; and one patient (who experienced massive intral-
esional hemorrhage and amputation) received none.Thirty
four patients received two cycles of IMAP chemotherapy
and ® ve received one cycle. Only eight patients received the
full three cycles of MAP chemotherapy concomitant with
preoperative irradiation; 12 patients received two cycles;
14 patients received one cycle; and 5 patients received
none. With median follow up of 33 months (8± 51 mo.)
four patients have died of metastatic disease and a ® fth
died N.E.D. in a motorcycle accident.Two patients have
experienced only local recurrence and a total of eight
have experienced only metastasis (including the four who
died).
Maturing Kaplan-Meier curves suggest favorable
survival and time to metastasis experience with this
regimen.
WE DO NEED TO CONFIRM THE RESULTS
OF SMALL CHEMOTHERAPY TRIALS IN
ADVANCED SOFT TISSUE SARCOMA WITH
RANDOMIZED STUDIES:THE
EXPERIENCE OF THE EORTC SOFT
TISSUE AND BONE SARCOMA GROUP
(STBSG)
M.Van Glabbeke,A. van Oosterom, A.Azzarelli,
A. Le Cesne, H. Mouridsen, J. Radford,
S. Rodenhuis, J. W. Oosterhuis, C. Hermans,
J.Verweij
EORTC Data Center and STBSG, Brussels, Belgium
For the last 20 years, the (STBSG) has conducted succes-
sive clinical trials testing new agents and combinations in
patients with non pretreated advanced soft tissue sarcoma.
Initial results are generally con® rmed in large phase III
randomized trials.The present work reviews the usefulness
of this procedure, and compares the results of the con® rma-
tion trials with those of the initial trials.
In 1982, a randomized phase II trial of Ifosfamide (IFOS)
vs Cyclophospamide showed a response rate of 25% in 38
patients treated with IFOS (5 g/m2, 24 hr infusion, q 3
wks). In 1992, the same regimen used as the control arm in
a randomized phase II trial showed 5% responses in 49
patients.
The original promising IFOS results encouraged the
group to test, in 1984, IFOS 5 g/m2 combined with Doxo-
rubicine (DOX) 50 mg/m2. In an initial non randomized
study, a response rate of 34% was obtained in 203 patients.
On this basis, the group embarked in 1985 on a rand-
omized phase III trial,comparing this combination to DOX
alone (75 mg/m2); this study did not show any signi® cant
advantage of the IFOS-DOX combination, where 28%
responses were observed in 297 patients.
The next step was to increase the dose of DOX to
75 mg/m2 in the combination, which was made possible
by the addition of growth factors. A pilot study with
IFOS 5 g/m2, DOX 75 mg/m2 and GmCSF conducted
in 1988 showed a response rate of 46% in 111 patients;
in 1992, the group started a randomized trial comparing
this regimen to the previous ª standard doseº regimen.
Response rates were not statistically signi® cant, and
substantially lower than those observed in the initial non
randomized trials: 21% in the standard dose regimen and
60 Abstracts23% in the high dose regimen (to be compared with the
34% and 46% of the initial pilot studies). Despite these
large differences in response rates, no major differences
were observed in survival between all these trials.
These results underline the danger of historical control
and small size studies in this disease. The pro® le of
patients referred to ® rst line chemotherapy had probably
changed over time, and the number of histological
subtypes may be responsible for large heterogeneity in
recruited patients. Randomization and strati® cation for
known prognostic factors does overcome these problems.
Response rate is probably not a valid end-point for
comparing chemotherapy regimen in this disease. External
review of response which is now a standard practice of
the group may partially explain the decrease in response
rates observed in our trials.
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